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DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY?:
REGULATORY REFORM OF HUMAN CLINICAL RESEARCH TO
RAISE RESPONSIVENESS TO THE REALITY OF HUMAN
VARIABILITY

MICHAEL J. MALINOWSKI* AND GRANT G. GAUTREAUX**
ABSTRACT
Scathing critiques of the Food and Drug Administration’s (“FDA”)
performance by the Government Accountability Office and Institutes of
Medicine, a plummet in innovative new drug approvals in spite of significant
annual investment increases in biopharmaceutical research and development
(“R&D”), and market controversies such as the painkiller Vioxx and the
diabetes drug Avandia (both associated with significantly escalated risks of
heart attacks and strokes) have raised doubts about the sufficiency of FDA
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this Article, which builds upon the discussion presented here to directly promote acceptance of
the single subject research design in clinical research by Europe and the International Conference
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Gold Does Not Glitter in Human Clinical Research: A Law-Policy Proposal to Brighten the
Global “Gold Standard” for Drug Research and Development, 45 CORNELL INT’L LAW J.
(forthcoming 2012).
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regulation. This Article questions how prescription medicines reach the
market and proposes law-policy reforms to enhance the FDA’s science
standard for human clinical trials and new drug approvals. The core message
is that relying too heavily on clinical research data generated through the
global “gold standard” of group experimental design—reliance on statistical
analysis to compile and compare group averages—risks predicting little about
the actual impact of prescription medicines on individuals, including members
of the groups under study. This Article introduces a law-policy methodology
based upon commercial incentives and intervention by Congress and the FDA
to raise the science standard for human clinical research, and to make drug
development more closely parallel the reality of drug delivery in the practice of
medicine. The objectives of this proposal are to promote several pressing
needs: maximize drug performance and minimize adverse events; end the
pattern of putting new prescription medications on the market with too much
dependence on the medical profession to introduce meaningful clinical
understanding of drugs through patient use over time; improve
biopharmaceutical R&D decision making; align the regulatory standard with
the infusion of added precision associated with contemporary genetics-based
R&D; and realize more sound scientific information directly through the
regulatory process to support the integrity of science in an age of academiaindustry integration, aggressive commercialization, secrecy in science, and
constantly, rapidly evolving technology.
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“2007 was the single worst year for new drug approvals in a quarter century
and 2008 proved to be only slightly better.”1
“[T]he drug industry’s research productivity has been declining for 15 years,
‘and it certainly doesn’t show any signs of turning upward’. . . .”2
“At present, our best advice for anyone concerned with the pharmaceutical
treatment of behavior disorders in people with developmental disabilities is
simple: Be skeptical and collect data.”3
INTRODUCTION
“Emma will never speak” was the conclusion of health care professionals
when she was assessed for significant learning disabilities at the age of three.4
Confirming what her parents had suspected and feared for much of her life,
these health care professionals diagnosed Emma with an autism spectrum
disorder.5 Autism or not, Emma’s parents did not accept the notion that their
1. G. Steven Burrill, Polishing the Crystal Ball: G. Steven Burrill Predicts What’s Ahead
for Biotech in 2009, BURRILL REPORT (Jan. 2, 2009), http://www.burrillreport.com/article980.html. The FDA approved eighteen innovative new drugs in 2007, twenty-four in 2008, and
twenty-six in 2009. Ed Silverman, How Many New Drugs Did FDA Approve Last Year?,
PHARMALOT (Feb. 18, 2011, 9:35 AM), http://www.pharmalot.com/2011/02/how-many-newdrugs-did-fda-approve-last-year; New Drug Approvals on Pace to Exceed 2008 Total, RES.
RECAP (June 9, 2009), http://www.alacrastore.com/blog/index.php/2009/06/09/new-drug-approv
als-on-pace-to-exceed-2008-total. But see Miho Nagano, Big Pharma Looks for a Fix,
INVESTOR’S BUS. DAILY, Sept. 29, 2008, at A9 (stating seventeen approvals in 2007). See infra
notes 146–49 and accompanying text.
2. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y.
TIMES, Jan. 23, 2011, at A1 (quoting Dr. Francis S. Collins, Director of the National Institutes of
Health, in a story on the federal government’s decision to launch a billion-dollar drug
development center to help industry create new pharmaceuticals).
3. Alan Poling et al., Pharmaceutical Interventions and Developmental Disabilities, in
DEVELOPMENTAL DISABILITIES: ETIOLOGY, ASSESSMENT, INTERVENTION, AND INTEGRATION
105, 120 (W. Larry Williams ed., 2004). Poling’s article also states that:
Few, if any, psychotropic drugs have been adequately evaluated in people with
developmental disabilities, despite repeated calls for further research. . . . As in years past,
further research is needed to produce data that will guide physicians in accurately
matching drugs to patients. . . . The use of single-case research methods may make it
easier to conduct research, although these methods have been used infrequently in clinical
psychopharmacology.
Id. at 119.
4. This case study is derived from Dr. Gautreaux’s work with children diagnosed with
severe learning disabilities. “Emma” is a fictional name, and identifiers have been excluded to
protect the family’s privacy. Similar anecdotal and scientific accounts have been published. See,
e.g., CATHERINE MAURICE, LET ME HEAR YOUR VOICE 11–25 (1993).
5. See AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS 66–67 (4th ed. 1994) (describing the diagnostic features of “Autistic Disorder”).
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daughter would never speak, and especially the prognosis that nothing could be
done to help her. They researched non-stop and exploited every resource to
find appropriate educational support. Their efforts led to entering Emma into a
program staffed by teachers focusing on her particular situation and taking
moment-to-moment data on her responses, graphing and analyzing even
minute components of her day. Teachers, working in close collaboration and
constantly comparing and analyzing data, used the detailed information drawn
from Emma and several other students clinically very similar to her to
generate, implement, and test—individually and collectively—a litany of
highly individualized interventions in an ongoing manner. Within a little more
than one year, Emma acquired some functional speech, demonstrated learning
at increasingly higher rates, showed IQ score improvements, and was
successfully entered into a program that mainstreamed her with children
developing according to “typical” indicators.
The interventions—both
successful and unsuccessful—and accompanying, detailed data were derived
from the tactics and strategies in the applied behavioral literature. Most of
these interventions became the subject of a series of publications in the science
literature to the benefit of other teachers, children, and the field in general.
Emma’s story illustrates the cumulative effect yielded from single subject
research design (“SSRD”), which entails a systematic implementation of the
scientific method to analyze and treat behavioral problems.6 SSRD, a natural
science methodology for human clinical research, developed in practice and
has been addressed in literature for over a half a century in disciplines such as
behavior analysis, education, physical therapy, and occupational therapy.7

6. SSRD is explained infra at Part I.B. For illustrations of SSRD see, JANINE E. JANOSKY
81–95 (2009). “The single subject design is a
family of designs that share fundamental concepts and methodologies.” Id. at 9. It is important
to note that the literature often commingles single subject studies with “N-of-1” (“number-ofone”) trials, which may be trials literally involving a single subject. Most SSRD experiments
involve focused studies of and between multiple participants. Gina Green, Single-Case Research
Methods for Evaluating Treatments for Autism Spectrum Disorders, 8 SPEAKER’S J. 69, 73–74
(2008) (describing the SSRD method). For additional background information on SSRD and
scientific research methods generally, see DAVID H. BARLOW ET AL., SINGLE CASE
EXPERIMENTAL DESIGNS: STRATEGIES FOR STUDYING BEHAVIOR CHANGE (3d ed. 2009)
(discussing the origins of SSRD and detailing SSRD methods and issues); MURRAY SIDMAN,
TACTICS OF SCIENTIFIC RESEARCH: EVALUATING EXPERIMENTAL DATA IN PSYCHOLOGY 2
(1960) (discussing important points in evaluating scientific research); B.F. SKINNER, THE
BEHAVIOR OF ORGANISMS: AN EXPERIMENTAL ANALYSIS (1938) (providing the foundation for
modern-day behavior analysis); John Carey, Medical Guesswork: From Heart Surgery to
Prostate Care, The Health Industry Knows Little About Which Common Treatments Really Work,
BUS.WK., May 29, 2006, at 72 (discussing the benefits believed to be provided when using
“evidence-based” medicine).
7. See Robert H. Horner et al., The Use of Single-Subject Research to Identify EvidenceBased Practice in Special Education, 71 EXCEPTIONAL CHILD. 165, 165–66 (2005); see also
ET AL., SINGLE SUBJECT DESIGNS IN BIOMEDICINE
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With SSRD, evidence-based practices are identified vis-à-vis replication rather
that the aggregate of results en masse. SSRD is an alternative to group
experimental design (“GD”), the global “gold standard” for human clinical trial
research in drug development.8 GD is based in randomized, parallel, group
trials.9 While GD typically focuses on ascertaining statistically significant
variations based upon group averages,10 the core SSRD methodology is to
repeat comparisons of control and treatment conditions with the same

JOHN O. COOPER ET AL., APPLIED BEHAVIORAL ANALYSIS 201 (2d ed. 2007) (describing
multiple baseline design as a research tactic for evaluating treatment effects in behavior analysis);
J. M. JOHNSTON & H. S. PENNYPACKER, STRATEGIES AND TACTICS OF BEHAVIORAL RESEARCH
296–309 (2d ed. 1993) [hereinafter JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS]
(discussing SSRD and GD in the context of behavior analysis); J. M. JOHNSTON & H. S.
PENNYPACKER, READINGS FOR STRATEGIES AND TACTICS OF BEHAVIORAL RESEARCH 3–7 (2d
ed. 1993) [hereinafter JOHNSTON & PENNYPACKER, READINGS] (discussing behavior analysis as
a natural science); ALAN E. KAZDIN, HISTORY OF BEHAVIOR MODIFICATION: EXPERIMENTAL
FOUNDATIONS OF CONTEMPORARY RESEARCH (1978) (tracing the history of experimentation in
behavior modification, a field that leans heavily on SSRD type methodologies); Steven C. Hayes,
Single Case Experimental Design and Empirical Clinical Practice, 49 J. CONSULTING &
CLINICAL PSYCHOL. 193 (1981) (arguing that SSRD is a good fit for clinical psychology); Mark
Wolery & Susan R. Harris, Interpreting Results of Single-Subject Research Designs, 62
PHYSICAL THERAPY 445 (1982) (discussing the interpretation of SSRD results in the context of
physical and occupational therapy); infra Part I.B. For thoughtful guidance on the use of SSRD
in applied psychology, see Neville M. Blampied, Single-Case Research and the ScientistPractitioner Ideal, in APA HANDBOOK OF BEHAVIOR ANALYSIS (Gregory J. Madden ed.,
forthcoming 2012) [hereinafter Blampied, Single-Case]. For a tutorial on SSRD, see Neville M.
Blampied, Univ. of Canterbury, Single-case Research: Useful Tools for 21st Century Applied
Science, Address at the Society for the Quantitative Analyses of Behavior 34th Annual Meeting
(May 28, 2011) (PowerPoint presentation on file with the Saint Louis University Law Journal)
[hereinafter Blampied Presentation]. A video of Professor Blampied’s tutorial presentation is
available at http://www.sqab.org/tutorials.php.
8. JANOSKY ET AL., supra note 6, at 81–82; see infra note 42–43, 86–88 and accompanying
text.
9. JANOSKY ET AL., supra note 6, at 81; see infra note 43 and accompanying text.
10. See infra Part I.B (offering a comparative discussion of GD and SSRD). Although
averages may be compiled based upon the mode (a variable that occurs the most frequently), the
mean (the total occurrence divided by the number of subjects), or the median (the occurrence in
the lies in the middle) of a group under study, group design generally centers on determining
statistically significant variations between the group that is receiving the treatment and those that
are not. See ALAN POLING ET AL., FUNDAMENTALS OF BEHAVIOR ANALYTIC RESEARCH 161–62
(1995); William W. Rozeboom, Good Science is Abductive, not Hypothetico-Deductive, in WHAT
IF THERE WERE NO SIGNIFICANCE TESTS? 335, 335–38 (Lisa L. Harlow et al. eds., 1997)
(discussing the pitfalls of significance testing); STEPHEN T. ZILIAK & DEIRDRE N. MCCLOSKEY,
THE CULT OF STATISTICAL SIGNIFICANCE 123–130 (2008) (detailing and criticizing the rise of
statistical significance in psychology research);. Statistical formulas are derived to account for
complexity, but they are based upon these averages. Rozeboom, supra. Interestingly,
“[a]veraging across individuals had its origins in a philosophical/religious attempt to remove the
effects of original sin from measurement of humans.” Blampied Presentation, supra note 7, at 27.
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individual or staggered across similar individuals, graph the data on a subjectby-subject basis, and analyze the results.11 Thus, the individual serves as her
own control while the variables interacting between the individual and the
environment are isolated. Such a finely grained approach enables the
researcher to obtain valuable information about both the individual and the
intervention, and more carefully police threatening complications. This
research approach has not been utilized in drug development: “Although there
is a long tradition of employing single subject designs in social science
research, these designs have only recently been utilized in biomedicine.”12
This Article proposes law-policy reform of human clinical trials in drug
development to promote the use of SSRD. A primary, overarching goal is to
advance the transition from traditional pharmaceutical R&D, with its focus on
taking away symptoms, to actually treating the causes of disease—at the
cellular, genetic, and molecular levels.13 Specifically, the Article challenges

11. Green, supra note 6, at 74; JANOSKY ET AL., supra note 6, at 81; DAVID L. MORGAN &
ROBIN K. MORGAN, SINGLE-CASE RESEARCH METHODS FOR THE BEHAVIORAL AND HEALTH
SCIENCES 27–30 (2009); Jaan Valsiner, Where is the Individual Subject in Scientific Psychology?,
in THE INDIVIDUAL SUBJECT AND SCIENTIFIC PSYCHOLOGY 11 (Jaan Valsiner ed., 1986). SSRD
is discussed in detail infra at Part I.B. For an excellent, accessible summary of SSRD
methodology, see generally Blampied Presentation, supra note 7. For discussion of SSRD in the
context of applied psychology, see Blampied, Single-Case, supra note 7.
12. JANOSKY ET AL., supra note 6, at 81; see also Green, supra note 6, at 69.
13. See infra Part II.B. This Article focuses on human clinical trials, not basic (“bench”)
studies. Reflective of the vast complexity and dynamism of human genetics—an estimated
23,000 genes responsible for all human variability, and the intense, ongoing interface of genes
and environmental factors in human health—and the nascent state of genetic science at this time,
there is tremendous dependence on group studies at the very beginning of the drug development
continuum. American Health Lawyers Association’s Advisory Council on Racial and Ethnic
Diversity, Patient-Tailored Medicine Part One: The Impact of Race and Genetics on Medicine, J.
HEALTH & LIFE SCI. L., Oct. 2008, at 1, 7 [hereinafter Patient-Tailored Medicine Part One];
American Health Lawyers Association’s Advisory Council on Racial and Ethnic Diversity,
Patient-Tailored Medicine, Part Two: Personalized Medicine and the Legal Landscape, J.
HEALTH & LIFE SCI. L., Jan. 2009 at 1, 5–7 [hereinafter Patient-Tailored Medicine Part Two]. A
rough map of the human genome determined “active” was completed just years ago (2003), and
efforts to purify that map and to fully decode the human genome are still underway. Human
Genome Project Information, U.S. DEPT. OF ENERGY, http://www.ornl.gov/sci/techresources/Hu
man_Genome/home.shtml (last updated July 25, 2011). Now scientists in the field of epigenetics
are studying the “other human genome”—heritable changes in gene function that occur without a
change in DNA. See Gary Felsenfeld, A Brief History of Epigenetics, in EPIGENETICS 16 (C.
David Allis et al. eds., 2007); Adrian Bird, Perceptions of Epigenetics, 447 NATURE 396, 396
(2007); see generally JAMES A. GOODRICH & JENNIFER F. KUGEL, BINDING AND KINETICS FOR
MOLECULAR BIOLOGISTS (2007) (discussing qualitative measurements of biological binding
reactions, “which are the fundamental building blocks of all complex biological systems”). For a
richer discussion of the genome, see ERIC H. DAVISON, THE REGULATORY GENOME: GENE
REGULATORY NETWORKS IN DEVELOPMENT AND EVOLUTION (2006). For further discussion of
epigenetics, see the articles contained in Epigenetics, 293 SCI. 1063–106 (2001), and NOVA:

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

370

SAINT LOUIS UNIVERSITY LAW JOURNAL

[Vol. 56:363

the FDA’s extensive reliance on the GD model, which has governed clinical
research since not too long after enactment of the Food, Drug and Cosmetic
Act in 1938,14 and suggests law-policy reforms to increase SSRD studies in
drug development. A major premise is that regulation of human clinical trials
should be responsive to the governing science, and SSRD emphasizes the
reality of human variability15 in a manner in sync with contemporary genetic
science and the actual practice of medicine.16 The core message is that relying
on data generated through GD alone—again, group averages compiled through
statistical analysis to test hypotheses—risks predicting little about the actual
impact of prescription medicines on individual patients at the detriment of
ongoing and future drug development, to the loss of multiple tens of millions
of living patients waiting for treatments, who are suffering from ongoing,
seriously debilitating, and even life-threatening human health ailments.17 Such

Epigenetics (PBS television broadcast July 24, 2007), available at http://www.pbs.org/wgbh/no
va/sciencenow/3411/02.html. In sum, at the base level of genetic science, comparisons are made
between multiple individuals at the genetic level, at times entire populations (“biobanks”), to sort
through this vast universe of variables and identify points for study. See generally Symposium,
Regulation of Biobanks, 33 J.L. MED. & ETHICS 1 (2005) (offering articles discussing biobanks
and biobanking issues); Symposium, Proceedings of “The Genomics Revolution? Science, Law
and Policy”, 66 LA. L. REV. (Special Issue) 1 (2005) [hereinafter Genomics Revolution] (offering
articles discussing the necessity for biobanking to meet the needs of genomics research); see also
Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Profiling in Drug
Development, 2 HOUS. J. HEALTH L. & POL. 31 (2002) (noting the law, policy, and market
implications of pharmacogenomics). Lars Noah, The Coming Pharmacogenomics Revolution:
Tailoring Drugs to Fit Patients’ Genetic Profiles, 43 JURIMETRICS J. 1, 7–11 (2002) (discussing
the potential for pharmacogenomic research to enhance pharmaceutical therapies). Therefore, this
Article appreciates the distinction between genetic studies at the molecular level from human
clinical trials to treat individuals, and the discussion centers on the latter. Comparing the utility
of GD and SSRD at the base level of drug development is beyond the scope of this Article.
14. “The first of the so-called miracle drugs, Sulfanilamide, led to the adoption of the
Federal Food, Drug, and Cosmetic Act of 1938 which emphasized premarketing safety of drugs,
based on scientifically designated animal and clinical studies.” STEVEN E. PEGALIS, AMERICAN
LAW OF MEDICAL MALPRACTICE § 17:13 (3d ed. 2005).
15. It is important to note that, while “human variability” is assumed and considered innate
to humans in group experimental design, in SSRD human variability is considered external and is
able to be controlled by accounting for extraneous variables. See infra Part I.B.
16. See Patient-Tailored Medicine Part One, supra note 13, at 7: see generally Genomics
Revolution, supra note 13 (offering articles discussing contemporary genetic science and issues in
genomics). Genetic specificity in contemporary biopharmaceutical R&D is addressed infra at
Part II.B.
17. As observed by other commentators in the context of patient-tailored medicine and racebased genetics research:
To predict therapeutic outcomes in individual patients, drug makers rely on statistical
analyses of a targeted population’s response to the medication in question. Thus, a
practitioner’s choice of drug often is based on population averages. Therefore, the current
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a reliance on this type of analysis may conceivably mask potentially effective
treatments for individuals and life-threatening complications for others.
A major focus of discussion is the nexus between the regulation of drug
development and the delivery of health care. Under the present law-policy
scheme, drug review is too lenient,18 practical yet sophisticated understanding
of new pharmaceuticals is too limited, and market approval invites excessive
off-label use—an approach that muddles clinical care with clinical research
excessively, and exacerbates the unpredictability of prescription medications.19

method of developing drug therapy focuses on large patient populations as groups,
irrespective of the potential for individual, genetically-based differences in drug response.
Patient-Tailored Medicine Part One, supra note 13, at 7. The extent to which drug sponsors have
been permitted to generalize over human variation in clinical research is extraordinary. For
example, throughout most of the twentieth century, women and children typically were excluded
from the groups studied to bring many of our familiar pharmaceuticals to market—including
pharmaceuticals for conditions that impact women and children, such as asthma and heart disease.
See Sarah K. Keitt, Sex & Gender: The Politics, Policy, and Practice of Medical Research, 3
YALE J. HEALTH POL’Y L. & ETHICS 253, 253 (2003). The rationale was to work to avoid groups
deemed “protected” under federal regulations to protect human subjects—including women, the
unborn, and children—and subject to more scrutiny, coupled with failure to appreciate the
hormonal and other biological differences between men and women, adults and children, or the
strategic choice to avoid complicating trials with factors such as the female hormonal cycle,
menopause, and puberty. Id. at 254–55; Karen H. Rothenberg, Gender Matters: Implications for
Clinical Research and Women’s Health Care, 32 HOUS. L. REV. 1201, 1206–10 (1996).
Accordingly, out of necessity, doctors prescribed medicines on the market to treat women and
children in spite of a dearth of data about those uses. For example, the doses for children have
been adjusted at doctor discretion based upon weight—similar to veterinary practice today. See
Barbara A. Noah, Just a Spoonful of Sugar: Drug Safety for Pediatric Populations, 37 J.L. MED.
& ETHICS 280, 281–82 (2009). The 1993 NIH Revitalization Act requires inclusion of women in
Phase III clinical studies and gender-based analysis of research results. National Institutes of
Health Revitalization Act of 1993, Pub. L. No. 103-43, §131, 107 Stat. 122, 133–35 (codified at
42 U.S.C. § 289a-2 (2006)). The Best Pharmaceuticals for Children Act (“BPCA”) codified
patent extension incentives for drug sponsors to include children and created a trust fund for the
FDA to do the same when drug sponsors refuse—conducting its own trials directly or through
contracted third parties. See Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115
Stat. 1408 (2002) (codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.).
18. In addition to the limitations of GD addressed throughout this Article, the efficacy
standard for market approval based upon that data is to be better than a placebo or sugar pill,
meaning to be better than nothing. See infra note 58 and accompanying text.
19. See infra Part III.A. Congress has responded to the problem, but this Article questions
its fix through the Food and Drug Administration Amendments Act of 2007 (“FDAAA”) because
of the ongoing fundamental reliance on GD. See infra notes 23–25 and accompanying text.
“[N]either Congress nor the FDA has attempted to regulate the off-label use of drugs by doctors
and consumers. A physician may prescribe a legal drug to serve any purpose that he or she deems
appropriate, regardless of whether the drug has been approved for that use by the FDA.” Wash.
Legal Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir. 2000). Off-label use of pharmaceuticals is
generally accepted in the medical community and commonly practiced. Wash. Legal Found. v.
Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in part on other grounds sub nom.
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Ultimately, the medical profession exercises expansive prescription discretion,
on and off FDA-approved labels, to sort through the actual safety, efficacy, and
peculiarities of a drug patient-by-patient, and over time—typically years—after
the drug is on the market.20 As documented in one empirical study, “Off-label
prescribing is very common in all areas of medicine. It is not uncommon for a
drug to be prescribed more often off-label than on-label. . . . Indeed, 80 percent
to 90 percent of pediatric patient regimens involve at least one off-label
prescription.”21 Ironically, off-label usage has been common practice for
individuals with developmental disabilities and autism, while some physicians
do not always recognize applied behavior analysis as a validated treatment for
autism due to the apparent dearth of large scale GD studies.22
Congress has recognized and addressed the problem through sweeping
legislation known as the Food and Drug Administration Amendments Act of
2007 (“FDAAA”).23 The methodology of FDAAA is to “augment premarket
clinical studies” and try to cull more from resulting data “with new sources of
evidence about the risks and benefits of drugs,” but the Act does not change

Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing that “off-label use of
FDA-approved drugs by physicians is an established aspect of the modern practice of medicine”);
see Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 350 (2001) (noting that off-label use
of medication is not only accepted in the medical community, but a “necessary corollary of the
FDA’s mission to regulate . . . without directly interfering with the practice of medicine”).
20. The same often is true with new medical devices and procedures. An illustrative
example of this point is the debate over when women should have mammograms. After decades
of relying upon group numbers to strongly encourage all women over the age of forty years to
have mammograms annually, the U.S. Preventive Services Task Force, based upon actual patient
experience with the technology, now discourages the presumption and emphasizes the importance
of a case-by-case, physician-patient, individualized approach. Danielle Dellorto, Task Force
Opposes Routine Mammograms for Women Age 40–49, CNN HEALTH (Nov. 16, 2009), http://ar
ticles.cnn.com/2009-11-16/health/mammography.recommendation.changes_1_routine-mam
mograms-mammography-task-force?_s=PM:HEALTH. For more information on the task force
and its projects, see U.S. Preventive Services Task Force, U.S. DEPT. OF HEALTH & HUMAN
SERV., http://www.ahrq.gov/clinic/uspstfix.htm (last visited Dec. 29, 2011).
21. Daniel B. Klein & Alexander Tabarrok, Do Off-Label Drug Practices Argue Against
FDA Efficacy Requirements? A Critical Analysis of Physicians’ Argumentation for Initial
Efficacy Requirements, 67 AM. J. ECON. & SOC. 743, 744, 755 (2008). As observed by these
authors, “Most cancer and AIDS patients are given drugs that are not FDA certified for the
prescribed use. In a large number of fields, a majority of patients are prescribed at least one drug
off-label.” Id. at 744 (citations omitted).
22. See Poling, supra note 3, at 119–20; Autism Spectrum Disorders: Treatment Options,
NAT’L INST. OF MENTAL HEALTH, http://www.nimh.nih.gov/health/publications/autism/treat
ment-options.shtml (last updated July 22, 2009). Off-label use is extremely pervasive in
pediatrics, and data for the pharmaceutical treatment of behavior disorders in people with
developmental disabilities is grossly insufficient. See Klein & Alexander, supra note 21, at 755;
Poling, supra note 3, at 119–20.
23. Pub. L. No. 110-85, 121 Stat. 823 (codified as amended in scattered sections of 21
U.S.C.).
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reliance on GD as the gold standard in drug development.24 Rather, the core
methodology of FDAAA is to do more with GD—in essence, to rely on it
more.25 Continued over-reliance on GD in human clinical studies coupled with
extensive medical community discretion to essentially experiment on patients
without systematically contributing to the research base—as opposed to
clinical researchers experimenting on research subjects under human subject
protections and direct FDA oversight—threatens to perpetuate a crude working
standard for prescription medications as they enter the market and for years
thereafter. This regulatory approach is increasingly unacceptable in an age of
genetic science.26
This Article begins by profiling GD in human clinical trials—again, the socalled gold standard and the cornerstone of the law-policy rubric governing
market approval for human medicinal products.27 Tremendous reliance on GD
has been reinforced globally through the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (“ICH”) standard sharing.28 Part I then introduces SSRD in an
interdisciplinary, comparative manner through discussion that draws from a
debate over GD and SSRD in human clinical studies developed in another
health care context—the field of applied behavior analysis (“ABA”).29
Specifically, the Comprehensive Application of Behavior Analysis to
Schooling Program (“CABAS®”) at Columbia University’s Teachers College
has utilized SSRD in research with and treatment of children with behavioral
conditions and often severe learning disabilities, many labeled “autistic,” and,
24. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and
Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L. REV. 419, 420, 434 (2010)
[hereinafter Evans, Seven Pillars]. For a thorough discussion of the FDAAA, see id., and Barbara
J. Evans, Authority of the Food and Drug Administration to Require Data Access and Control
Use Rights in the Sentinel Data Network, 65 FOOD & DRUG L.J. 67 (2010) [hereinafter Evans,
Authority].
25. See Evans, Seven Pillars, supra note 24, at 425.
26. For discussion of the impact of genetic science on drug development methodology and
the associated potential to raise precision, see infra Part II.B.
27. See supra notes 8–9 and accompanying text.
28. Several guidances for clinical trials originally developed by the ICH have been adopted
by the FDA and published in the Federal Register. See, e.g., International Conference on
Harmonisation; Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583 (Sept.
16, 1998); International Conference on Harmonization; Good Clinical Practice: Consolidated
Guideline, 62 Fed. Reg. 25,692 (May 7, 1997); see generally ICH Guidance Examines Statistical
Principles to Support Clinical Research, GUIDE TO GOOD CLINICAL PRAC. NEWSL. (Thompson
Publishing Group, Inc., Wash., D.C.), Nov. 1998, at 5, available at 6 No. 2 CLINPRAC-NWL 5
[hereinafter ICH Guidance Examines]. For general information about the ICH, visit its official
website, http://www.ich.org (last visited Dec. 29, 2011).
29. See COOPER ET AL., supra note 7, at 201–24 (discussing a popular research method in
applied behavior analysis); JOHNSTON & PENNYPACKER, READINGS, supra note 7, at 16–17;
JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS, supra note 7, at 296–309.
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more recently, neuro-typical children.30 This is a highly protected group under
the regulations to protect human subjects31—one that has been too often
overlooked and avoided in clinical research for drug development and yet
routinely prescribed medications that reach the market.32 CABAS®, with a
legacy of three decades of research and an international network of schools and
graduates working in the field, has challenged the preexisting norms of heavy
reliance on GD in clinical research and generated significant research
accomplishments and documented treatment interventions.33 In addition to the
shared context of clinical research, treatment for patients with developmental
disabilities depends heavily—arguably, often too heavily—on utilization of
prescription medicines made available through the drug development process
without data sufficient for physicians to match drugs and patients.34 These
practices, in addition to raising cautionary concerns regarding unknown side
effects, may also lead to an unsubstantiated yet alluring false efficacy.
Part II frames ongoing disappointments and frustrations with contemporary
drug development and challenges the entrenched reliance on GD. Specifically,
this Part questions continued dependence upon mathematical abstracts that,
although representative of the group collectively, may say nothing decisive
about members of the group individually, let alone broad populations of
patients with health care needs outside the group. The discussion concludes
that the core regulatory process to put drugs on the market lingers from the
past and is disconnected from the patient-centered nature of the practice of
medicine and the science disciplines that dominate today’s innovative
biopharmaceutical R&D. Part III proposes a regulatory overhaul of clinical
research to modify the gold standard through utilization of SSRD. This
proposal draws from past efforts by Congress and the FDA to shape clinical
trial research through both direct mandates and commercial incentives,

30. R. Douglas Greer & Dolleen-Day Keohane, A Real Science and Technology of
Education, in EVIDENCE-BASED EDUCATIONAL METHODS 23, 37–38 (Daniel J. Moran &
Richard. W. Malott eds., 2004) [hereinafter Greer & Keohane, Real Science]; R. Douglas Greer et
al., The Effects of the Verbal Developmental Capability of Naming on How Children Can Be
Taught, 1 ACTA DE INVESTIGACIÓN PSICOLÓGICA 23, 26–27 (2011); R. Douglas Greer &
Dolleen-Day Keohane, The Evolution of Verbal Behavior in Children, BEHAV. DEV. BULL. 31
(2005), reprinted in 1 J. SPEECH LANGUAGE PATHOLOGY & APPLIED BEHAV. ANALYSIS 111,
112–13 (2006).
31. 45 C.F.R. §§ 46.401–.409 (2010) (establishing children as one of the protected groups
within overall human subject protection regulations). For discussion of the absence of children in
drug development research, see infra notes 248–268.
32. See supra note 17.
33. See Greer & Keohane, Real Science, supra note 30, at 37–41.
34. See supra note 17; Poling, supra note 3, at 119.
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including the Best Pharmaceuticals for Children Act (“BPCA”)35 and the
Orphan Drug Act (“ODA”).36
I. THE “GOLD STANDARD” IN HUMAN CLINICAL RESEARCH AND THE SSRD
ALTERNATIVE
The following discussion summarizes the evolution of GD as the gold
standard for clinical research and drug approval with a focus on the
accompanying law-policy rubric that promotes it.37 The discussion then
profiles SSRD as an alternative natural science research methodology for
human clinical research that, although increasingly recognized in biomedicine
in recent years, remains highly underutilized in biopharmaceutical R&D.38
A.

The Science and Law-Policy Rubric for Human Clinical Research

The law-policy surrounding human clinical trials reflects the regulatory
role the FDA has evolved into during the decades after enactment of the Food,
Drug, and Cosmetic Act of 1938 (“FDCA”).39 The FDCA bestowed the
Agency with the powers to assume a market gatekeeper role—the authority to
examine, question, and evaluate the clinical utility of drugs.40 Still, prior to
1970, the Agency made law primarily by pursuing judicial enforcement of
statutory standards.41 Subsequently, the Agency has shifted in the direction of
an administrative law-policy approach—exercising its capacity as product
reviewer and rule-maker—and has raised the burden on drug sponsors to earn
market approval. As observed by authors Hutt, Merrill, and Grossman, “Faced

35. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002)
(codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.).
36. Orphan Drug Act, Pub. L. No. 97-414, § 2, 96 Stat. 2049, 2049–51 (1983) (codified as
amended in scattered sections of 21 U.S.C. and 42 U.S.C.).
37. See infra notes 43–44, 92–94 and accompanying text.
38. JANOSKY ET AL., supra note 6, at 81.
39. Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040
(codified as amended at 21 U.S.C. §§ 301–399 (2006)) (“FDCA”). The FDCA has been amended
more than 100 times. Peter Barton Hutt, A Historical Introduction, 45 FOOD DRUG COSM. L.J. 17
(1990), as reprinted in PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 4 (3d ed. 2007). The
Agency we now know as the FDA was created by the Federal Food and Drugs Act of 1906.
Federal Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (repealed 1938); John P.
Swann, About FDA: FDA’s Origins, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/About
FDA/WhatWeDo/History/default.htm (last visited Dec. 29, 2011).
The Act prohibited
adulterated and misbranded food and drugs and introduced an administrative enforcement clause
to enable implementation. Paul Hyman, U.S. Food and Drug Law and FDA—A Historical
Background, in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 21 (Kenneth
R. Piña & Wayne L. Pines eds., 1st ed. 1998).
40. Richard A. Merrill, The Architecture of Government Regulation of Medical Products, 82
VA. L. REV. 1753 (1996), as reprinted in HUTT ET AL., supra note 39, at 5.
41. HUTT ET AL., supra note 39, at viii.
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with increasingly complex substantive issues and a growing number of firms
making regulated products, FDA turned toward rulemaking as the principal
technique for defining legal requirements. The agency attempted to resolve
most of the major issues it confronted through administrative, rather than court,
action.”42 The FDA, as product reviewer and market gatekeeper, has been
responsive to clinical trial data of effectiveness generated through
implementation of the GD gold standard—randomized, parallel, group clinical
trial designs.43 The standard has been adopted globally, as recognized by the
ICH in E9 Statistical Principles for Clinical Trials. The ICH issued E9 in
1998 to harmonize statistical methodologies used to support marketing
applications.44 The ICH serves as an advisory body for drug harmonization for
the European Union (“EU”) through the European Medicines Agency
(“EMA”), the United States through the FDA, and Japan through the Ministry
of Health, Labor, and Welfare.45 In 2008, the ICH developed technical
requirements for registration of pharmaceuticals for human use.46 The
requirements defined key terms in the discipline of pharmacogenomics,
including pharmacogenetics, genomic biomarkers, and genomic data, and
provided sample drug coding categories.47 The intent was “to develop
42. Id.
43. Id. at 624; JANOSKY ET AL., supra note 6, at 81–82; Carey, supra note 6, at 77.
44. See generally ICH Guidance Examines, supra note 28; International Conference on
Harmonisation; Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583, 49,584
(Sept. 16, 1998). The ICH has developed shared scientific standards for clinical data and good
clinical practice. Michael J. Malinowski, Ethics in a Global Biopharmaceutical Environment, 5
SANTA CLARA J. INT’L L. 57, 70–71 (2006), http://www.scujil.org/sites/default/files/volumes/v5_
MalinowskiArticle.pdf.
For information about the ICH, visit its official website,
http://www.ich.org (last visited Dec. 29, 2011). Six conferences have been held to date, and a
seventh (the “ICH7 Conference”) was scheduled to take place March 29–30, 2006, in Vienna,
Austria, but was cancelled. ICH Steering Committee Meeting Summary 7 (June 5–8, 2006),
available at http://www.ich.org/uploads/media/SC_Report_Yokohama_2006.pdf.
The
organization itself, with representatives from both government and industry, operates in an
ongoing manner. For an international extension of this Article that directly addresses the ICH,
see Michael J. Malinowski & Grant G. Gautreaux, All that is Gold Does Not Glitter in Human
Clinical Research: A Law-Policy Proposal to Brighten the Global “Gold Standard” for Drug
Research and Development, 45 CORNELL J. INT’L LAW (forthcoming 2012).
45. Vision, ICH, http://www.ich.org/about/vision.html (last visited Dec. 29, 2011).
46. See International Conference on Harmonisation; Guidance on E15 Pharmacogenomics
Definitions and Sample Coding, 73 Fed. Reg. 19,074 (Apr. 8, 2008).
47. Id. at 19,075. Pharmacogenomics and pharmacogenetics are defined and discussed infra
at notes 48, 135, and 238 and accompanying text. In simplest terms, genomics is the science of
genetic expression and its influence on human health. Genomics and Health, CTRS. FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/genomics/public/index.htm (last updated Apr. 26,
2010). The discipline has become prevalent at the forefront of drug development, with
completion of the map of the human genome announced in 2003. See supra note 13 and
accompanying text. A biomarker is “[a] biochemical feature or facet that can be used to measure
the progress of disease or the effects of treatment.” Definition of Biomarker, MEDICINENET,

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2012]

DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY?

377

harmonized approaches to drug regulation” and “to ensure that consistent
definitions of terminology are being applied across all constituents of the
[ICH],” as well as the “integration of the discipline of pharmacogenomics
[(“PG”)] and pharmacogenetics into the global drug development and approval
processes.”48 In 2010, the ICH developed requirements for the context,
structure, and format of voluntary biomarker submissions from PG research in
order to create a “harmonized recommended structure for biomarker
qualification” that will allow for consistency of applications and will “facilitate
discussions with and among regulatory authorities.”49 Between the three
regulatory entities enveloped in the ICH, all three adhere to these standards,
but at this point no standards have been developed to integrate PG into
mainstream healthcare.
The resulting quid pro quo for market access is data generated through GD
in four phases (sometimes classified as five) of clinical trials.50 Phase I trials
generally are conducted in tens of healthy volunteers for up to a month with
the objective of making the transition from animal to human participants
through research on toxicity and a showing of safety.51 Minimum doses are
administered, and the healthy status of participants enhances the transparency
of their impact.52 With a focus on safety, the core objective of these trials is to
assess the metabolic and pharmacological actions of the drug candidate in

http://www.medterms.com/script/main/art.asp?articlekey=6685 (last reviewed Apr. 27, 2011).
The FDA provides a table of genomic biomarkers used in approved drug labels at Table of
Pharmacogenomic Biomarkers in Drug Labels, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (last visited Dec. 29,
2011).
48. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics
Definitions and Sample Coding, 73 Fed. Reg. at 19,075.
49. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., GUIDANCE
FOR INDUSTRY: E16 BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT
DEVELOPMENT: CONTEXT, STRUCTURE, AND FORMAT OF QUALIFICATION SUBMISSIONS 1 & n.1,
2 (2011).
50. See infra notes 51–64 and accompanying text. Deviations from the standard drug
approval clinical trial process described are granted for unusual circumstances, such as trials on
drug candidates for very small patient disease groups and those for highly innovative therapeutics
for presently untreatable conditions that will expose study participants to extremely high levels of
risk. The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD &
DRUG ADMIN., http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last
visited Dec. 29, 2011); see infra notes 268–69 and accompanying text; see also Risk and
Responsibility: The Roles of FDA and Pharmaceutical Companies in Ensuring the Safety of
Approved Drugs, Like Vioxx: Hearing Before the H. Comm. on Gov’t Reform, 109th Cong. 24–25
(2005) (statement of Steven Galson, Acting Director Center for Drug Evaluation and Research)
(outlining the pre-market approval process).
51. See 21 C.F.R. § 312.21(a) (2011).
52. HUTT ET AL., supra note 39, at 630–31.
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humans, and to identify side effects while increasing doses.53 Phase I trials
also may garner early evidence of effectiveness.54 Phase II trials involve
hundreds of participants drawn from the target disease group and span several
months.55 The objectives are to study the effectiveness of the new treatment,
to determine short-term side effects and overall risks associated with the drug,
and to develop advanced dosage criteria.56 Phase III typically encompasses
thousands of disease group participants at multiple sites with the goals of
balancing safety and efficacy, to refine dosage, and establish overall
effectiveness against a placebo (sugar pill) or other control.57
The data generated in Phase III shapes applications for market access. The
baseline standard for market approval is to outperform a placebo on efficacy,
perhaps just by a percentage point or two, with a showing of tolerable safety in
a defined population.58 Once biopharmaceuticals reach the market, the
medical community has broad discretion to use them off-label—and does so
aggressively.59 The FDA continues to regulate pharmaceuticals post-market
approval through Phase IV follow-on trials that probe lingering questions and
strive to perfect clinical use, that is, to develop additional details about the
product’s safety and efficacy.60 Congress has attempted to shift traditional

53. 21 C.F.R. § 312.21(a).
54. Id. With an increase of innovative new drug candidates, Phase I trials have been
modified in recent years to occasionally include efficacy testing in terminally ill patients
particularly where there are nonexistent or insufficient existing treatments, thereby comingling
traditional Phases I and II and clinical research and care. See Jamie L. Aldes, Note, The FDA
Clinical Trial Process: Effectuating Chance in the Regulatory Framework Governing Clinical
Trials to Account for the Historical Shift from “Traditional” to “New” Phase I Trials, 18
HEALTH MATRIX 463, 473–74 (2008).
55. Aldes, supra note 54, at 471.
56. 21 C.F.R. § 312.21(b) (2011).
57. Id. at § 312.21(c). Stuart R. Cohn & Erin M. Swick, The Sitting Ducks of Securities
Class Action Litigation: Bio-Pharmas and the Need for Improved Evaluations of Scientific Data,
35 DEL. J. CORP. L. 911, 918 (2010); Geoffrey M. Levitt, The Drugs/Biologics Approval Process,
in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION, supra note 39, at 101. As
discussed infra at note 79 and in the accompanying text, over the last five years, typical Phase III
trials have expanded from 5,000 to 20,000 subjects and their cost has doubled to surpass $100
million. Nagano, supra note 1.
58. 21 C.F.R. § 314.126(a) (2010); Aldes, supra note 54, at 468. See generally W. John
Thomas, The Vioxx Story: Would it have Ended Differently in the European Union?, 32 AM. J. L.
& MED. 365 (2006) (discussing the approval of Vioxx under the American drug approval process
and contrasting the U.S. approval process with that of the European Union).
59. See supra notes 19–22 and infra note 115–19 and accompanying text.
60. Aldes, supra note 54, at 472; see 21 C.F.R. § 314.80 (2011); HUTT ET AL., supra note
39, at 734–38.
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Phase IV trials into premarket studies through the FDAAA.61 Phase IV studies
have been largely observational and centered on post-marketing surveillance to
detect and define previously unknown or inadequately quantified adverse
reactions and related risk factors.62 In recent years, these studies often have
distinguished defined demographic groups that may have been overlooked as a
focus point during the trials that put the drugs on the market.63 Areas of
inquiry may involve formulation evaluations, dosages, the durations of
treatment, and interactions with other medications.64
A major trend since implementation of the Food and Drug Administration
Modernization Act of 1997 (“FDAMA”) has been to err in favor of putting
new drugs on the market on a watch-and-see basis to introduce access for
patients in need, albeit conditioned with follow-on studies—often referred to as
506B studies.65 This approach is consistent with expansion of the FDA’s
mission under FDAMA to include efficiency, along with efficacy and safety,
for new drug approvals.66 Unfortunately, the FDA has been lax in enforcing
these post-market study conditions.67

61. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, § 901,
121 Stat. 823, 922–43; Evans, Seven Pillars, supra note 24, at 477; see generally Evans,
Authority, supra note 24; Malinowski & Gautreaux, supra note 44.
62. Post-marketing surveillance is sometimes referred to as “Phase V” trials. See Aldes,
supra note 54, at 472 (“Phase V trials monitor the effects of the drugs as reported by physicians,
survey data, and discover new uses for the drug.”).
63. See Patient-Tailored Medicine Part Two, supra note 13, at 16–17 (discussing lack of
minority participants in clinical trials).
64. OFFICE OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUMAN SERVS., FDA’S
MONITORING OF POSTMARKETING STUDY COMMITMENTS 1 (2006).
65. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115,
§130, 111 Stat. 2296, 2231–32 (codified at 21 U.S.C. 356b). Section 506B of FDAMA, the
provision that promotes this presumption in favor of market approval, is codified under 21 U.S.C.
§ 356b. That same section provides FDA enforcement authority for 506B studies. 21 U.S.C. §
356b(d)–(e) (2006). See also OFFICE OF INSPECTOR GEN., supra note 64, at 1, 2–3 (discussing
506B post-marketing studies).
66. Christopher D. Zalesky, Considering Changes to CMS’s National Coverage Decision
Process: Applying Lessons Learned From FDA as a Regulator of Access to Healthcare
Technology, 57 FOOD & DRUG L.J. 73, 86 (2002); James L. Zelenay, Jr., The Prescription Drug
User Fee Act: Is a Faster Food and Drug Administration Always a Better Food and Drug
Administration?, 60 FOOD & DRUG L.J. 261, 295 (2005) (“PDUFA II [enacted in conjunction
with FDAMA] shifted the agency’s focus from one based solely on protecting the public from
unsafe and ineffective products, possibly at the cost of expediency, to one that must balance this
interest in safety with an interest in providing patients with speedy access to new drugs.”).
67. See U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-06-402, DRUG SAFETY:
IMPROVEMENT NEEDED IN FDA’S POSTMARKET DECISION-MAKING AND OVERSIGHT PROCESS
18–23 (2006) (finding the FDA lacks a clear and effective process for post-market drug safety
decision making); INST. OF MED., THE FUTURE OF DRUG SAFETY: ACTION STEPS FOR CONGRESS
1 (2006) (noting FDA’s lack of clear authority to enforce compliance).
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FDA regulations and standards for clinical trial study design distinguish
exploratory trials from confirmatory trials and hold the former to more rigid
standards.68 With the most common study design, parallel group experimental
design, participants are randomized to one or more trial arms, and each arm is
allocated a different treatment.69 Ideally for the purposes of generating and
collecting data both for safety and efficacy, GD comparisons are drawn
between a group of participants taking the drug candidate and another
administered a placebo to show statistically significant differences between
group mean scores.70 Double-blinding (neither the administering physician nor
the participants know who actually is receiving the drug candidate) is used to
check the risk of bias.71 However, in practice, it tends to be much more
complicated to incorporate participants’ access to existing treatments into the
studies. Research subjects are administered the drug candidate coupled with
an existing standard-of-care treatment.72 Comparisons are made with groups

68. As explained under the ICH E9 Guidance, which incorporates FDA standards,
exploratory trials “cannot be the basis of the formal proof of efficacy, although they may
contribute to the total body of relevant evidence.” International Conference on Harmonisation;
Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583, 49,587 (Sept. 16,
1998). The Guidance “suggests that sponsors conducting confirmatory trials estimate the size of
the effects of the investigational product and relate the estimate to actual clinical significance.
Because the hypothesis to be tested is largely based on clinical results and because a single
confirmatory trial may be used to establish efficacy, adherence to the protocol and standard
operating procedures is a must . . . .” ICH Guidance Examines, supra note 28.
69. Green, supra note 6, at 70–71.
70. See id. Testing against a placebo is testing against nothing, which is the extreme
comparison—the greatest means to document efficacy data in patient group research. See id.
71. International Conference on Harmonisation; Guidance on Statistical Principles for
Clinical Trials, 63 Fed. Reg. at 49,587. The E9 Guidance recommends using double-blinding
where investigational “treatments are prepacked with a randomization schedule, and supplied to
the trial center(s) labeled only with the subject number and the treatment period so that no one
involved in the conduct of the trial is aware of the specific treatment allocated to any particular
subject.” Id. According to the Guidance, blind breaking should only occur when the trial
subject’s physician deems it necessary; if blind breaking does occur, it “should be reported and
explained at the end of the trial.” Id. A trend increasing in recent years is for study participants
to use modern technology to remove their half of the double-blind—from internet access to
communication with other subjects via patient group chat rooms and blogs that enable collective
information and comparisons, to sending blood samples to independent laboratories to discern
directly whether they are getting the drug candidate. LAWRENCE M. FRIEDMAN ET AL.,
FUNDAMENTALS OF CLINICAL TRIALS 87 (3d ed. 1996).
72. Ethics norms for domestic U.S. research, as embodied in the Common Rule, ban denial
of access to existing treatments with instances of seriously debilitating and life-threatening
conditions. See Paul Litton & Franklin G. Miller, A Normative Justification for Distinguishing
the Ethics of Clinical Research from the Ethics of Medical Care, 33 J.L. MED. & ETHICS 566, 570
(2005) (“[U]nder the seven principles for research, it would be unethical to withhold effective
treatment to such ill persons for research purposes if withholding treatment exposes a person to
grave risk.”). For the same reason, once data establishes efficacy and safety during a trial to
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given the standard treatment alone or, where there are multiple treatment
options, the drug candidate with varied couplings.73
Since the introduction of the Prescription Drug User Fee Act in 1992
(“PDUFA”), the FDA has been granting accelerated approval of novel drugs
based upon surrogate endpoints—laboratory measures that suggest
improvements in patient health rather than factual documentation of actual
impact given a contained timeframe—in accordance with formal clinical
standards, meaning patient health improvements.74 Inferences about the drug
candidates are based on statistical comparisons of group mean scores.75 The
ultimate compilation is a statistical common denominator across the full target
disease population.
A major limitation in GD for drug development is that human variability
among study participants may prove significantly more substantial than
anticipated even though, symptomatically, the subjects appear to share what
has been classified a disease.76 The mathematical abstract derived from the
population may predict nothing for any individual participant. As explained by
Professor Janosky,
[P]atients are unique and may not respond similarly to various treatments, and
in those instances a randomized clinical trial design may be inappropriate.

develop treatments for such conditions, study sponsors typically must make the drug candidate
available to all of those in its trials. Id.
73. See supra note 72 and accompanying text.
74. 21 C.F.R. § 314.510 (2010). The ICH E9 Guidance suggests that,
In choosing which clinical endpoints to test for, the guidance recommends that sponsors
select primary endpoints capable of providing the most clinically relevant and convincing
evidence directly related to the trial’s main objective. Typically, there should be but one
primary endpoint. Usually, efficacy should be the primary endpoint, although safety,
tolerability, or quality-of-life measurements also may serve as the foremost endpoints to
be tested, the guidance states.
ICH Guidance Examines, supra note 28. The FDA has been criticized for accepting surrogate
endpoints for accelerated, conditional market approval and then failing to enforce follow-on study
requirements. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-09-866, NEW DRUG APPROVAL:
FDA NEEDS TO ENHANCE ITS OVERSIGHT OF DRUGS APPROVED ON THE BASIS OF SURROGATE
ENDPOINTS 29 (2009). According to the GAO, the FDA has required over 144 studies since
introducing the accelerated approval program in 1992. Id. at 18. More than a third of those are
still pending and the Agency never has pulled a drug for failure to conduct long-term studies. Id.
at 18, 29. The FDA does not routinely check whether companies are making progress on required
studies. Id. at 29–32.
75. See supra notes 10, 17 and accompanying text (explaining the use of averages in GD
statistics).
76. This point is illustrated in a discussion of the tremendous genetic diversity associated
with the health care condition categorized as “dwarfism.” See Michael J. Malinowski, Dealing
with the Realities of Race and Ethnicity: A Bioethics-Centered Argument in Favor of Race-Based
Genetics Research, 45 HOUS. L. REV. 1415, 1451–57 (2009) (profiling the Roloff family from the
television show “Little People, Big World” as a case study).
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Guidelines are established from the averaged study findings, which may not
necessarily be applicable when evaluating suitable treatment options for
individuals. Specifically, patients treated in primary care settings may differ
clinically from patients in the clinical trial, the patient diversity in the clinical
trial may not generalize to certain patient populations, and the stringent trial
criteria for accepting participants may not accurately reflect general patient
77
populations.

The effort to account for human variability and to generate a meaningful
predictor of drug performance through GD, to the extent that is possible,
demands thousands of participants at multiple locations—a need that has
increased substantially over the last decade and pushed drug sponsors to
outsource both toxicology studies and human clinical trials to contract research
organizations (“CRO”).78 “In the past, a single phase three trial might have
needed 3,000 patients and cost between $10 million and $20 million. Today,
the same kind of study would take 20,000 patients and cost $50 million to $100
million . . . .”79 While the trend is expansion of clinical trial recruitment
outside of the U.S. borders,80 “[t]he number of clinical trials in the United
States has climbed dramatically in recent years. Between 2000 and 2006,

77. JANOSKY ET AL., supra note 6, at 81–82 (footnotes omitted). The renowned Dr. Jerome
Groopman has reached the same conclusion: “Statistics cannot substitute for the human being
before you; statistics embody averages, not individuals. Numbers can only complement a
physician’s personal experience with a drug or a procedure, as well as his knowledge of whether a
‘best’ therapy from a clinical trial fits a patient’s particular needs and values.” JEROME
GROOPMAN, HOW DOCTORS THINK 6 (2007). Similarly, as observed by another commentator:
The best way to go from intuition to evidence is the randomized clinical trial.
Patients with a particular condition are randomly assigned to competing treatments or, if
appropriate, to a placebo. By monitoring the patients for months or years, doctors learn
the relative risks and benefits of the treatment being studied.
But such trials take years and cost many millions of dollars. By the time the results
come in, science and medicine may have moved on, making the findings less relevant.
Moreover, patients in a clinical trial usually aren’t representative of real people, who
tend to have complex combinations of diseases and medical problems. And patients often
don’t stick with the program.
Carey, supra note 6, at 77 (emphasis added).
78. Nagano, supra note 1.
79. Id.
80. Id. In addition to the speed of subject recruitment (the primary driver for expansion of
recruitment outside of the United States),
To seek bigger patient pools, most major CROs have expanded operations overseas to
India, Russia, Latin America, Eastern Europe and other emerging markets. U.S.-based
CROs have a presence in more than 70 countries.
In those countries, CROs can easily find a large number of “treatment-naïve
patients” who aren’t taking other drugs and are thus the best candidates for trials.
Id.
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clinical trials increased from 40,000 to 59,000—a nearly 50 percent jump.”81
Though industry is spending unprecedented amounts on clinical research and
conducting more and larger clinical trials, the sobering outcome is a steep drop
in innovative new drug approvals in recent years.82
Congress has recognized and responded to the drug development dilemma
by forcing more of GD through the FDAAA and culling more data around it
rather than questioning the methodology.83 The current administration is
concerned enough to introduce a billion-dollar center, funded in a time of
economic trouble, to infuse government-performed research assistance in order
to help industry put more new drugs on pharmacy shelves.84
B.

The Advent and Evolution of SSRD

SSRD is a natural science research methodology developed in practice and
addressed in literature for over a half a century in disciplines such as behavior
analysis, education, physical therapy, and occupational therapy.85 “Although
there is a long tradition of employing single subject designs in social science
research, these designs have only recently been utilized in biomedicine,”86 and
“these
methods
have
been
used
infrequently
in
clinical
psychopharmacology.”87 However, the cross-discipline popularity of SSRD is
on the rise: “In recent literature, it appears these designs are receiving more
recognition, as they are being increasingly employed in research across
disciplines.”88
The core SSRD methodology is to repeat comparisons of control and
treatment conditions with the same individual or staggered across similar
individuals, graph the data on a subject-by-subject basis, and then analyze the
resulting data.89

81. CTR. FOR HEALTH & PHARM. LAW & POLICY, SETON HALL LAW, WHITE PAPER:
CONFLICTS OF INTEREST IN CLINICAL TRIAL RECRUITMENT & ENROLLMENT: A CALL FOR
INCREASED OVERSIGHT 5 (2009).
82. See infra Part II.
83. See supra notes 23–25 and accompanying text.
84. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y.
TIMES, Jan. 23, 2011, at A1.
85. See supra note 7 and accompanying text. For detailed discussion of the SSRD
methodology, see JANOSKY ET AL., supra note 6, at 25–43.
86. JANOSKY ET AL., supra note 6, at 81; see also id. at 81–96 (discussing direct application
of SSRD in biomedicine).
87. Poling et al., supra note 3, at 119.
88. JANOSKY ET AL., supra note 6, at 82.
89. Green, supra note 6, at 74. “In a single-case experiment, each data point represents one
of the repeated direct measurements of the target behavior, as opposed to a mathematical abstract
like a group mean test score. Graphing those data provides a picture of exactly how behavior
unfolds in real time under specific conditions.” Id. at 78.
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Single-case design experiments to evaluate treatment effects involve directly
observing and measuring one or more specific behaviors of an individual
repeatedly for a period of time while a particular treatment is not in place (the
control or baseline condition), and while it is (the experimental or treatment
condition). . . . Comparisons of control and treatment conditions are repeated,
90
or replicated, with the same individual and/or with other similar individuals.

Human variability is accounted for in single subject research by
manipulating environmental variables that occasion steady states of
responding—rather using statistical analysis to herd subjects into what are
declared to be steady states for the individual, but actually represent only group
averages. Specifically,
In applied single-case studies, the interest is not in statistically significant
differences between group mean scores but in clinically and educationally
important improvements in individual behavior in comparison to baseline. In
many behavior analytic studies, those changes—that is, differences in data
from the control and treatment conditions—far exceed what is required for
statistical significance. Individual differences in responses to treatment and
variability in behavior are not viewed as “noise” to be wiped out
mathematically, but as natural features of behavior to be studied further so they
can be better understood. Replication, which is an essential ingredient of
science, is built into single-case designs. . . . The evidence for those
conclusions comes from conditions where the treatment and other variables are
tightly controlled and the effects of the treatment on behavior are observed
directly, rather than from statistical transformations of numbers that do not
91
represent actual behavior.

The SSRD and GD methodologies for responding to variability in
outcomes are fundamentally different.92 In GD, researchers typically use large
samples to average out differences in outcomes, while SSRD researchers
attempt to bring outcome differences under experimental control—in other
words, statistical control over error through large samples under GD, versus
experimental control to reduce error with a heightened focus on individual
subject responses under SSRD.93 As pointed out by Professor Janosky,
[The GD] strategy is problematic for two reasons: (1) statistical power and
sample size are related, with larger samples at times leading to significant but
very small effects with little pragmatic value and (2) it discourages the
researcher from strategically modifying treatment (i.e., response guided
94
experimentation) that may positively impact most if not all the patients.

90.
note 7.
91.
92.
93.
94.

Id. at 74. For an overview on SSRD methodology, see Blampied Presentation, supra
Green, supra note 6, at 78–79.
JANOSKY ET AL., supra note 6, at 28.
Id.
Id.
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In contrast, under SSRD, patient responsiveness is probed through
modification of, and changes in, the treatment as a consequence of responseguided experimentation.95
Ultimately, the objective driving drug development must be the
improvement of patient health. The medical community effectively engages in
a simulation of SSRD through often creative patient-by-patient treatment with
biopharmaceuticals under its discretion to use them off-label—a “cart before
the horse approach” so to speak. In the words of some thoughtful observers,
“[t]o some extent, clinical medicine always has been tailored to the patient in
that each physician-patient relationship is unique, and each clinical encounter
represents the physician’s attempt to provide the optimal care to the patient in
the examining room, the emergency room, the hospital bed, and the intensive
care unit.”96
SSRD’s focus on the individual has made the methodology a natural fit for
the field of behavior analysis.97 In fact, much of the groundwork is attributable
to B.F. Skinner and dates back to the 1930s:
Skinner emphasized studying the individual to determine lawful models of
behavior. He drew heavily upon animal research, often using pigeons or rats,
to uncover fundamental learning principles that could then be applied to
humans. Inevitably, similar procedures for modifying behavior were applied
to individual human subjects. Within the realm of applied behavior analysis,
single subject design studies began examining methods for modifying behavior
of individuals with diverse psychological problems, including stuttering,
98
learning disabilities, mental retardation, and psychotic symptoms.

SSRD has had a profound impact in the treatment of individuals with
autism spectrum disorder and other severe learning disabilities.99 For example,
the CABAS® model, a comprehensive approach to behavior analysis and
schooling,100 has yielded an abundance of procedures, tactics, interventions,
and large scale protocols for parents, educators, and children with a wide

95. Id.
96. Patient-Tailored Medicine Part One, supra note 13, at 9.
97. See Green, supra note 6, at 73. As explained by Professor Green, “[l]ike other scientists,
behavior analysts have devised research methods that are suited to their particular subject matter,
while meeting all of the general requirements of science.” Id. at 73. These requirements include
careful observation, objective measurement, controlled experiments, analysis and interpretation of
data, and repetition (replication) of experiments. Id. at 70. Because the focus is on individual
behavior unfolding over time, single-case research designs are used for most behavior analytic
studies. These are true experiments, not “case studies” or nonexperimental observational studies.
Id. at 74.
98. JANOSKY ET AL., supra note 6, at 28 (citations omitted). R.A. Fisher introduced the first
official single subject clinical trial experimental paradigm in 1945. Id. at 1.
99. See supra note 33 and accompanying text.
100. See supra note 33 and accompanying text.
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variety of disabling conditions.101 The underlying theme of all CABAS®
research is adhering to scientific rigor based on John Stuart Mill’s five canons
of the scientific method.102 Through tightly controlled scientific studies
conducted by practitioners, CABAS® research has promoted the growth and
development of academic social repertoires for children, and generally enabled
learning and function in thousands of children deemed “unteachable.”103
While education is a field susceptible to trends, untestable theories, and heavy
reliance on construct attributes, SSRD has allowed the field of behavior
analysis to establish grounded, effective approaches and documented success
with severely learning-disabled children through natural science evaluation in
human clinical research. Interestingly, while SSRD methods have been
developed through and used significantly in ABA, they have been used
infrequently in clinical psychopharmacology.104
II. DRUG UNDERDEVELOPMENT
Throughout much of the twentieth century and into the present one,
pharmaceutical research and development (“R&D”) has been the most
profitable sector.105 For decades, our tendency as patients and consumers has
been to believe that prescription medications improve human health and, in
turn, to associate medicine closely with science—especially when grappling
There have been profound
with a seriously debilitating illness.106
improvements to human health through pharmaceuticals for well over a half
century,107 but the overall reality is that the prescription medication arsenal to
treat all human ailments prior to the 1990s consisted of merely 2000–3000
commercial pharmaceuticals derived from 483 drug targets (compounds that
serve as the basis for medicinal applications).108

101. See Greer & Keohane, Real Science, supra note 30, at 37–38.
102. See R. DOUGLAS GREER, DESIGNING TEACHING STRATEGIES: AN APPLIED BEHAVIOR
ANALYSIS APPROACH 161–163 (2002).
103. Joe Levine, The Unorthodox Behaviorist, TC TODAY, Spring 2007, at 24, 26–27.
104. Poling et al., supra note 3, at 119.
105. MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES, at xv (2004).
106. See PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE, 336–37
(1982) (detailing a growing dependence on pharmaceuticals and medical technology following
World War I).
107. See, e.g., id. at 335–36 (noting, for example, advances in antibiotics and Malaria
control).
108. Jürgen Drews, Drug Discovery: A Historical Perspective, 287 SCI. 1960, 1962 (2000);
Michael J. Malinowski, Respecting, Rather than Reacting to, Race in Basic Biomedical Research:
A Response to Professors Caulfield and Mwaria, 45 HOUS. L. REV. 1489, 1492 n.16 (2009);
Thomas Reiss, Drug Discovery of the Future: The Implications of the Human Genome Project,
19 TRENDS BIOTECHNOLOGY 496, 496 (2001). “This surprisingly low number of targets
illustrates that the identification of clinically relevant and interesting targets was the primary
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The Twentieth Century Drug Development Experience

The crudeness of the underlying science relied upon is self-evident in the
twentieth century drug development experience. Historically, developers
would sort through thousands of drug targets to produce just one
pharmaceutical success.109 The endeavor focused on taking away the
symptoms of disease—not on understanding and treating the causes of
disease.110 “[D]rug discovery essentially was a linear process based upon
screening and testing of thousands of chemicals and natural substances for
potential therapeutic activity. Screening was time consuming and largely
random because drug targets and drug functions were in most cases
unknown.”111 Compounds were introduced in living organisms to identify
their effect and potential medicinal utilities, purified to control toxicity in
conjunction with at least one medicinal use, and introduced onto the market
with the expectation that physicians would experiment further while practicing
medicine on patients and identify additional clinical utilities through off-label
uses.112
Drug sponsors were not even required to demonstrate efficacy for market
access until 1962.113 The regulatory standard for market approval of a drug
candidate in the United States has been eliminating symptoms, even if just
marginally more effectively than a placebo, coupled with a showing that
adverse events and other safety issues across the target disease population are
tolerable given the benefits.114 This standard, paired with the discretion of

bottleneck of the drug discovery process.” Patient-Tailored Medicine Part One, supra note 13, at
12.
109. Drug Discovery and Development, PHRMA, http://www.Phrma.org/research/drugdiscovery-development (last visited Dec. 29, 2011).
110. See Evans, Seven Pillars, supra note 24, at 439–44 (discussing efficacy as the purpose of
randomized, controlled clinical trials).
111. Patient-Tailored Medicine Part One, supra note 13, at 11–12 (citing Press Release, Tufts
Ctr. for the Study of Drug Dev., Backgrounder: How New Drugs Move Through the
Development and Approval Process (Nov. 2001), available at http://csdd.tufts.edu/files/uploads/
how_new_drugs_move.pdf); see generally Jim Gilbert et al., Rebuilding Big Pharma’s Business
Model, IN VIVO: BUS. & MED. REP., Nov. 2003, at 73 (2003), available at www.bain.com/bain
web/PDFs/cms/Marketing/rebuilding_big_pharma.pdf (outlining the traditional methods that
have led the drug industry to profit loss, including a random, all-inclusive, expensive testing
process).
112. See supra notes 19–22 and accompanying text.
113. Thomas, supra note 58, at 372; Patient-Tailored Medicine Part One, supra note 13, at
24; Harris Meyer, Costly Stamp of Approval, L.A. TIMES, Jan. 18, 2010, at E3. Sponsors have
been required to demonstrate safety since 1938. Id.
114. Patient-Tailored Medicine Part One, supra note 13, at 9 (“Nonetheless, not until the
second half of the twentieth century has much attention been paid to drug safety and, even then,
adverse drug reactions were considered part of the practice of medicine.”); David Classen,
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commercial sponsors to tailor clinical research and to apply (or not) for
approval of specific uses in applications for market access, has invited
tremendous off-label use by the U.S. medical profession once products reach
the market.115 Though the biopharmaceutical sectors spend tens of billions of
dollars on research annually,116 they spend more on marketing—both legal and
illegal.117 Much of their marketing is directed at encouraging the medical
community to exercise its discretion to use their products off-label.118 Offlabel use is motivated further by publication of industry-sponsored research in
science and medical journals, direct-to-consumer marketing,119 and patient
faith in new treatments, including experimental ones.120 Even when marketed
legally, only “[o]ne-third of all drugs act as expected when prescribed to
patients,” and there are approximately two million adverse drug reactions
requiring hospitalization each year.121 Adverse drug reactions cause more than

Medication Safety: Moving from Illusion to Reality, 289 JAMA 1154, 1154 (2003); Evans, Seven
Pillars, supra note 24, at 449.
115. See Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 350 (2001); Wash. Legal
Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir. 2000) (calling off-label use “commonplace”);
Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in part on other
grounds sub nom. Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing that
“off-label use of FDA-approved drugs by physicians is an established aspect of the modern
practice of medicine”).
116. PHARM. RESEARCHERS & MFRS. OF AM., PHARMACEUTICAL INDUSTRY PROFILE 26
fig.8 (2010); see CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 9 (calling the
cost of “nontreatment activities,” including research, considerable and substantial).
117. ANGELL, supra note 105, at 11–12. The FDA has estimated that almost two percent of
all prescription drugs—thousands of medicines that include powerful active ingredients such as
antihistamines, narcotics and sedatives—are marketed illegally without its approval. Meyer,
supra note 113.
118. Meyer, supra note 113 (explaining that high prices of FDA-approved drugs leads to use
of cheaper, unapproved off-label drugs).
119. ANGELL, supra note 105, at 123–26 (describing how direct-to-consumer advertising both
persuades and misleads consumers).
120. See INST. OF MED., supra note 67, at 2 (suggesting black triangle indicators for new drug
approvals to flag the lack of market history); Wylie Burke & Bruce M. Psaty, Personalized
Medicine in the Era of Genomics, 298 JAMA 1682, 1682–84 (2007) (detailing the potential of
experimental, genetically personalized pharmaceutical treatment).
121. Patient-Tailored Medicine Part One, supra note 13, at 9, 16–17; see also INST. OF MED.,
THE FUTURE OF DRUG SAFETY: PROMOTING AND PROTECTING THE HEALTH OF THE PUBLIC 54
box2-5 (2007) (relating drug-specific data on adverse effects as reported to the FDA).
To some extent, clinical medicine always has been tailored to the patient in that each
physician-patient relationship is unique, and each clinical encounter represents the
physician’s attempt to provide the optimal care to the patient in the examining room, the
emergency room, the hospital bed, and the intensive care unit. Nonetheless, not until the
second half of the twentieth century has much attention been paid to drug safety and, even
then, adverse drug reactions were considered part of the practice of medicine.
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100,000 deaths annually in the U.S.—meaning that more people in the U.S. die
from legal use of prescription medications than from automobile accidents.122
Medicine remains much more art than science:
Even today, with a high-tech health-care system that costs the nation $2 trillion
a year, there is little or no evidence that many widely used treatments and
procedures actually work better than various cheaper alternatives.
....
. . . And while there has been progress in recent years, most of these
physicians say the portion of medicine that has been proven effective is still
123
outrageously low—in the range of 20% to 25%.

B.

Today’s Drug Research and Development Potential

Drug development has changed fundamentally.124 The legacies of
discretion to commercial sponsors over the content of clinical research and to
the medical community over off-label use are prevalent today, but the science
of drug development has evolved and is undergoing a genomics (genetic
expression) metamorphosis—a “genomics revolution.”125 The prevalence of
“biopharmaceuticals” in the drug development pipeline and the centralized
review of all new drugs, whether based primarily in biology or chemistry,
within the Center for Drug Evaluation and Research (CDER) beginning in
2004126 confirm that pharmaceutical R&D and biotech have integrated
extensively.127

Today, because adverse drug reactions cause more than two million hospitalizations
and 100,000 deaths annually in the United States, there are strong clinical, economic, and
ethical imperatives to address the manifold causes of these numbers.
Patient-Tailored Medicine Part One, supra note 13, at 9 (footnotes omitted). See also BS
Shastry, Pharmacogenetics and the Concept of Individualized Medicine, 6 PHARMACOGENOMICS
J. 16, 16 (2006). Negative outcomes may result both from errors in prescribing and dispensing
and from individuals’ adverse reactions to the drugs themselves. Petra A. Thürmann, Prescribing
Errors Resulting in Adverse Drug Events: How Can They Be Prevented?, 5 EXPERT OPINION ON
DRUG SAFETY 489, 490 (2006). It is entirely possible that one of the causes of adverse drug
reactions is the method by which individual patients metabolize those drugs. Kathryn A. Phillips
et al., Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic
Review, 286 JAMA 2270, 2270 (2001).
122. Shastry, supra note 121, at 16. One 2005 report stated that approximately 40,000 people
are killed in automobile accidents every year. Miranda Hitti, Car Crashes Kill 40,000 in U.S.
Every Year, FOX NEWS (Feb. 3, 2005), http://www.foxnews.com/story/0,2933,146212,00.html.
123. Carey, supra note 6, at 73 (reporting on the movement for evidence-based medicine).
124. See generally STARR, supra note 106.
125. See generally Genomics Revolution, supra note 13; Nagano, supra note 1 (“The
consensus on Wall Street: Big Pharma’s business model is ‘broken, and no longer
working’ . . . .”).
126. See Press Release, U.S. Food & Drug Admin., FDA Completes Final Phase of Planning
for Consolidation of Certain Products from CBER to CDER, (Mar. 17, 2003), available at
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The potential of ongoing drug development, with a map of the human
genome in hand128 and the creation of more profound tools underway,129
arguably is limited only by human ingenuity given increasing abilities to
manipulate the “highly sophisticated, delicate regulatory pathways and

http://www.scienceblog.com/community/older/archives/M/2/fda1387.htm. Until 2004, biologic
drugs were reviewed by the Center for Biologics Evaluation and Research. Transfer of
Therapeutic Products to the Center for Drug Evaluation and Research, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/
CBER/ucm133463.htm (last visited Dec. 29, 2011). Where the drugs were a combination of
traditional and biotech, sponsors had some choice in where to file for review. Influenced by the
trend of biopharmaceuticals, all drug review and the relevant resources were centralized in
CDER. Id.
127. See Transfer of Therapeutic Products, supra note 126.
128. See Press Release, Nat’l Human Genome Research Inst., International Consortium
Completes Human Genome Project, (Apr. 14, 2003), available at http://www.genome.gov/
11006929 [hereinafter International Consortium]. The Human Genome Project (“HGP”),
commenced in 1990, was undertaken to identify and map the sequence of information coded in
DNA and to identify active human genes—segments of DNA. Id.; Patient-Tailored Medicine
Part One, supra note 13, at 10–11. A rough map of the human genome was completed in 2003,
years ahead of schedule. Patient-Tailored Medicine Part One, supra note 13, at 11. Information
about the HGP may be obtained from the National Human Genome Research Institute
(“NHGRI”) at www.nhgri.nih.gov/HGP. For more information on the human genome generally,
see the February 16, 2001 issue of Science entitled “The Human Genome,” 291 SCI. 1145 (2001)
and the February 15, 2001 Issue of Nature, 409 NATURE 745 (2001), also entitled “The Human
Genome” dedicated to a draft of the map of the human genome. See also SUBCOMM. ON HUMAN
GENOME OF THE HEALTH & ENVTL. RESEARCH ADVISORY COMM. FOR THE U.S. DEP’T OF
ENERGY, REPORT ON THE HUMAN GENOME INITIATIVE FOR THE OFFICE OF ENVIRONMENTAL
RESEARCH (1987), available at www.ornl.gov/sci/techresources/Human_Genome/project/herac
2.shtml (discussing the need for and value of a map of human DNA); Eric S. Lander, Scientific
Commentary: The Scientific Foundations and Medical and Social Prospects of the Human
Genome Project, 26 J.L. MED. & ETHICS 184, 184 (1998) (explaining the HGP and the
possibilities that arise with unlocking the “human periodic table”). Once genes are identified,
comparisons can be made among individuals to identify genetic variations and assess their
function and impact on human health. See CTR. FOR GENETICS EDUC., THE HUMAN GENETIC
CODE—THE HUMAN GENOME PROJECT AND BEYOND (2007), available at www.genet
ics.com.au/pdf/factsheets/fs24.pdf (noting diagnosis and predictive testing for genetic conditions).
129. See Press Release, Nat’l Human Genome Research Inst., International Consortium
Announces the 1000 Genomes Project (Jan. 22, 2008), available at http://www.1000ge
nomes.org/sites/1000genomes.org/files/docs/1000genomes-newsrelease.pdf.
An international research consortium today announced the 1000 Genomes Project, an
ambitious effort that will involve sequencing the genomes of at least a thousand people
from around the world to create the most detailed and medically useful picture to date of
human genetic variation. The project will receive major support from the Wellcome Trust
Sanger Institute in Hinxton, England, the Beijing Genomics Institute, Shenzhen (BGI
Shenzhen) in China and the National Human Genome Research Institute (NHGRI), part
of the National Institutes of Health (NIH).
Id.
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feedback loops”130 of drug targets through the precision of genetics and
identification of environmental influences.131 Today holds the promise of
infiltrating disease pathways on the cellular, genetic, and molecular levels to
treat the causes of disease and thereby improve human health well beyond
existing capabilities.132
The completion of the human genome map in 2003 made it possible to identify
an individual’s genetic makeup to determine disease risk, and a patient’s likely
response to certain medications. Genetic information may be used to diagnose
a condition in an individual prenatally or prior to the presentation of any
133
clinical symptoms.

Millions of associations have been made between genetic variations and
human health, and each constitutes a potential drug target.134 Increasingly,
discussion of a forthcoming era of personalized medicine—engineering
medications tailored to individual patient’s genetic makeup (pharmacogenetics,
developed through pharmacogenomics)135—and extensive genetic profiling as
part of both preventive care and treatment carries a tone of “when” rather than
“if.”136 Overall, there is considerable consensus that “the availability of the

130. Peter Imming et al., Drugs, Their Targets and the Nature and Number of Drug Targets,
5 NATURE REVIEWS: DRUG DISCOVERY 821, 830 (2006). A drug target is “a molecular structure
(chemically definable by at least a molecular mass) that will undergo a specific interaction with
chemicals that we call drugs because they are administered to treat or diagnose a disease. The
interaction has a connection with the clinical effect(s).” Id. at 821.
131. See supra note 13 for a discussion of epigenetics.
132. See BIOTECHNOLOGY INDUS. ORG., GUIDE TO BIOTECHNOLOGY 2008 32–40 (2008),
available at http://www.bio.org/node/2801 (discussing some of the therapies made possible by
recent research advances).
133. Patient-Tailored Medicine Part One, supra note 13, at 11.
134. William E. Evans & Mary V. Relling, Moving Towards Individualized Medicine With
Pharmacogenics, 429 NATURE 464, 466, 468 (2004). More than 3 million human genetic
variations, called single nucleotide polymorphisms (“SNPS”), had been identified by April 2003.
International Consortium, supra note 128.
135. In simplest terms, pharmacogenomics utilizes genetic profiling in pharmacology—for
example, centering a human clinical trial on members of a disease group under study who share a
particular genetic variation. When successful, the result is associations between specific human
genetic variations and responsiveness to pharmaceuticals, thereby enabling individualized
medicine based on genetic profiling, which is a field known as pharmacogenetics. See supra
notes 46–47 and accompanying text. Complementary fields are pharmacogenomics, which is
research centered on the expression of alleles shared by groups, and pharmacogenetics, the
tailoring of health care and biopharmaceuticals to individual genetic profiles. See Malinowski,
supra note 13, at 32; Noah, supra note 13, 7–11; Janet Woodcock, FDA Policy on
Pharmacogenomic Data in Drug Development, 66 LA. L. REV. 91, 92 (2005).
136. See Patient-Tailored Medicine Part One, supra note 13, at 6–7; Burke & Psaty, supra
note 120, at 1684; Susan B. Shurin & Elizabeth G. Nabel, Pharmacogenomics—Ready for Prime
Time?, 358 NEW ENG. J. MED. 1061, 1062–63 (2008). “Biotechnology also has created a wave of
new genetic tests. Today there are more than 1,200 such tests in clinical use, according to
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human genome sequence, together with the pharmacogenomic and
pharmacogenetic approaches to developing new drug therapies, has and will
continue to contribute to a better selection and faster development of safer and
more effective diagnostics and treatments.”137 Affirmations of the health care
potential of contemporary biopharmaceutical R&D include Herceptin,138
Gleevec,139 and Olaparib.140
C. Drug Disappointments and Desperation
Unfortunately, the present reality is that drug development lingers between
the scientifically crude, yet enormously profitable pharmaceutical past and the
biopharmaceutical present and future.141 “Ten years after President Bill
Clinton announced that the first draft of the human genome was complete,
medicine has yet to see any large part of the promised benefits.”142 The
transition could take many years—decades according to some
commentators.143 In recent years, drug development disappointments have
vastly outnumbered successes in spite of tremendous investment.144 According
to the pharmaceutical industry’s trade organization, the Pharmaceutical
Research and Manufacturers of America (“PhRMA”), “In 2009, America’s
pharmaceutical research and biotechnology companies continued to make the

genetests.org, a site sponsored by the University of Washington. Many are for genetic diseases,
while others test predisposition to disease. Emerging applications include tests to predict
response to medicines and assist with nutritional planning.” BIOTECHNOLOGY INDUS. ORG.,
supra note 132, at 32.
137. Patient-Tailored Medicine Part One, supra note 13, at 12. See also The Int’l SNP Map
Working Grp., A Map of Human Genome Sequence Variation Containing 1.42 Million Single
Nucleotide Polymorphisms, 409 NATURE 928, 932 (2001) (discussing the various benefits
anticipated from the human genome map).
138. See generally ROBERT BAZELL, HER-2: THE MAKING OF HERCEPTIN, A
REVOLUTIONARY TREATMENT FOR BREAST CANCER (1998).
139. Brian J. Druker, STI571 (GleevecTM) as a Paradigm for Cancer Therapy, 8 TRENDS
MOLECULAR MED. S14, S14 (2002).
140. Steven Reinberg, New Cancer Drug Fights Tumors in Those with BRCA Mutations, U.S.
NEWS & WORLD REP. (June 24, 2009), http://health.usnews.com/articles/health/healthday/2009/
06/24/new-cancer-drug-fights-tumors-in-those-with-brca.html.
141. See ANGELL, supra note 105, at xv–xvii; U.S. FOOD & DRUG ADMIN., INNOVATION OR
STAGNATION: CHALLENGE AND OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL
PRODUCTS (2004), available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/
CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf
(providing
a
comprehensive discussion on the challenges facing biopharmaceuticals, despite recent advances
in biomedical research, as well as potential solutions); Bitter Medicine: Pills, Profit, and the
Public Health (ABC News television broadcast May 29, 2002).
142. Nicholas Wade, A Decade Later, Gene Map Yields Few New Cures, N.Y. TIMES, June
13, 2010, at A1.
143. See Patient-Tailored Medicine Part One, supra note 13, at 35.
144. See supra notes 1–3 and accompanying text.
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world’s largest investment in pharmaceutical R&D, holding steady with $65.3
billion spent on R&D, including $45.8 billion by PhRMA members alone.”145
Nevertheless, new drug approvals fell to a twenty-five year low in 2007, just
eighteen, followed by a slight bump to twenty-four in 2008 and twenty-six in
In 2010, Pfizer Inc., the world’s largest research-based
2009.146
pharmaceutical company, did not produce a single new drug approval.147 In
comparison, new drug approvals peaked in 1996 when the FDA approved
fifty-three.148 According to Dr. Francis Collins, Director of the National
Institutes of Health, this decline in productivity over the past fifteen years
“certainly doesn’t show any signs of turning upward.”149 In fact, the federal
government has become concerned enough about the performance of the
commercial biopharmaceutical sectors to start a “billion-dollar government
drug development center to help create new medicines.”150 Industry continues
to spend enormous amounts of money to make new drugs.151
The drop in new drug approvals has taken place in spite of annual
governmental investments of billions of dollars in biomedical research and a
substantial increase in commercial investment in biopharmaceutical R&D.
“Before 1980, the National Institutes of Health (NIH) funded most medical
research. . . . Today, drug and medical device companies fund up to 80% to
90% of all clinical trials; in 2005, industry invested 78% more in research and
development than did the federal government.”152 Though the trend is to
export clinical research beyond the U.S. borders and to outsource it to
CROs,153 the amount of clinical research undertaken today within the United
States is unprecedented—an almost fifty percent increase during the first half
of this decade.154 Phase III trials have expanded to 20,000 subjects from just

145. PHARM. RESEARCHERS & MFRS. OF AM., supra note 116, at iii.
146. Jared A. Favole & Jennifer Corbett Dooren, FDA Approved More Drugs in 2008, WALL
ST. J., Jan. 2, 2009, at A9; New Drug Approvals on Pace to Exceed 2008 Total, supra note 1;
Silverman, supra note 1; see also Jenna Greene, Has Obama Redirected the Regulatory System?,
NAT’L L. J., Jan. 18, 2010, at 11 (noting that the number of FDA approvals under the Obama
administration are “on par or even more accommodating than” the Bush Administration); Pete
Harpum, Articulating a Vision for Best Practice Project Management in Drug Development, PM
WORLD TODAY, Oct. 2008, at 1, http://www.pmforum.org/library/papers/2008/PDFs/Harpum-1008.pdf.
147. See Asher Mullard, 2010 FDA Drug Approvals, 10 NATURE REVS.: DRUG DISCOVERY
82, 84 tbl.1 (2011) (listing CDER’s approvals in 2010 in chart form).
148. FDA’s Drug Approvals Flat 2009, Safety Up, MSNBC (Jan. 5, 2010, 1:37 PM),
http://www.msnbc.msn.com/id/34708085/ns/health-health_care/t/fdas-drug-approvals-flat-safety/.
149. Harris, supra note 2.
150. Id.
151. Id.
152. CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 6.
153. Nagano, supra note 1.
154. CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81, at 5.
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3,000 five years ago, which has doubled their cost—now typically $50–100
million.155
In addition to the decline in new drug approvals, many of the prescription
drugs the FDA has put on the market in recent years have proven
disappointing. There is ample reason to question their quality and the
Agency’s performance overseeing them.156 Most notably, Vioxx has become a
“scarlet letter” the FDA is likely to wear for years to come,157 and many
additional prescription drug problems have followed in recent years. In the fall
of 2010, the FDA itself “concluded that in some cases two types of drugs that
were supposed to be preventing serious medical problems were, in fact,
causing them.”158 These were Avandia, prescribed heavily to treat type-2
diabetes, and bisphosphonates—an active agent in the prescription drugs
Fosamax, Actonel, and Boniva—used widely to prevent fractures common in
people with osteoporosis.159 Avandia was associated with an increased risk of
heart attacks and strokes, a major problem for its target patient group given
two thirds of diabetics die of heart problems,160 and bisphosphonates was

155. Nagano, supra note 1.
156. See U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67; INST. OF MED., supra note 67.
157. Thomas, supra note 58, at 371–73.
158. Gina Kolata, When Drugs Cause Problems They Are Supposed to Prevent, N.Y. TIMES,
Oct. 17, 2010, at A18.
159. Id.
160. Id. The recent Avandia controversy triggered an expansive U.S. Senate Finance
Committee inquiry and bipartisan report highly critical of both GlaxoSmithKline (“GSK”) and
the FDA. See STAFF OF S. COMM. ON FINANCE, 111TH CONG., REP. ON GLAXOSMITHKLINE
AND THE DIABETES DRUG AVANDIA 1 (Comm. Print. 2010) [hereinafter REPORT ON AVANDIA].
This medication, introduced to the market in 1999 and prescribed to hundreds of thousands of
patients annually to treat type 2 diabetes, caused 83,000 heart attacks between 1999 and 2007,
according to the FDA’s own estimates. Id. at 1–4; Gardiner Harris, Research Ties Diabetes Drug
to Heart Woes, N.Y. TIMES, Feb. 20, 2010, at A1. GSK researchers identified a link between
Avandia and serious heart disease in 2004, 2005, and 2006, the FDA issued a warning in 2007,
the FDA’s top officials in the Office of Surveillance and Epidemiology recommended a full
market recall, and internal FDA reports indicated that switching Avandia patients to an alternative
drug could prevent about 500 heart attacks and 300 cases of heart failure each month. REPORT
ON AVANDIA, supra, at 14, 93; Harris, supra. According to the Senate Report, executives at the
pharmaceutical company “attempted to intimidate independent physicians, focused on strategies
to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought
ways to downplay findings that a competing drug might reduce cardiovascular risk.” REPORT ON
AVANDIA, supra, at 1. GSK responded by challenging the report and defending Avandia. Id. at
8. Although GSK is undertaking another round of clinical trials to research the increased risk of
heart disease, those are not projected to be completed until 2020. Harris, supra. Many
lawmakers, consumer advocates, and other stakeholders are calling for regulatory reform of the
FDA to grant officials in the Office of Surveillance and Epidemiology independent decisionmaking power on par with that of officials who approve drugs. Alyah Khan, Recent Avandia
Report Sparks Concerns Over Internal FDA Power Struggle, FDA WK., Feb. 26, 2010, at 4, 4.
This suggestion was made years earlier, including in the 2006 Institute of Medicine’s Report on
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determined to actually cause fractures of the thigh bone and degeneration of
the jawbone.161 In addition, a whole generation of teenagers with severe acne
was treated with Accutane, on the market in 1982, which now is associated
with inflammatory bowel disease, ulcerative colitis, Crohn’s disease, other
gastrointestinal disorders, liver damage, birth defects, and suicidal thoughts.162
Roche, the manufacturer, pulled Accutane from the market on June 29,
2009.163 Many commercial drug developers and their supporters blame the
FDA for the drop-off in new drug approvals, claiming the FDA has been too
strict.164 Others attribute the fall to an industry that is clinging to the low
science and regulatory standards of the past, stretching the commercial lives of
pharmaceuticals through manipulation of the patent system, and contriving
“me too” drugs rather than engaging in genuine innovation.165 When the
Vioxx controversy substantiated doubts about the FDA’s reliability in
regulating the biopharmaceutical market,166 the Agency responded by raising

the FDA and in the law literature. INST. OF MED., supra note 67, at 1, 3; see Thomas, supra note
58, at 379.
161. Kolata, supra note 158.
162. Steven Bushong, Accutane Off Shelves, but Lawsuits Live, COLUMBUS DISPATCH, July 3,
2009, at A1; Accutane Side Effects, DRUG WATCH, http://www.drugwatch.com/accutane/sideeffects.php (last modified Sept. 30, 2011).
163. Accutane Side Effects, supra note 162; Press Release, Roche Pharmaceuticals, Roche
Discontinues and Plans to Delist Accutane in the U.S. (June 29, 2009), available at
http://www.rocheusa.com/portal/synergy/static/file/synergy/alfproxy/download/1414-cd2ddc12
b4d211deadd62f6357bc6b3c/last/roche%20discontinues%20and%20plans%20to%20delist%20ac
cutane%20in%20the%20u.s..pdf.
164. For a thoughtful argument of over-regulation, see RICHARD A. EPSTEIN, OVERDOSE:
HOW EXCESSIVE GOVERNMENT REGULATION STIFLES PHARMACEUTICAL INNOVATION (2006).
Note, however, that Professor Epstein does not directly address or challenge the core proposal of
this Article—changing the core science standard in the context of the existing regulatory
infrastructure.
165. See ANGELL, supra note 105, at 7–10, 13–17.
The culture within the FDA, [is] one where the pharmaceutical industry, which the FDA
is supposed to regulate, is seen by the FDA as its client instead.” The lack of adequate
regulation of the pharmaceutical industry by the FDA has led to many deaths and recalls
of unsafe drugs, such as Vioxx, that the FDA had approved for public use [in 1999]. As
Sen. Charles Grassley (R-Iowa) explained, “[c]onsumers should not have to second-guess
the safety of what’s in their medicine cabinet.” Unfortunately, many consumers suffer as
a result of the current ineffective state of the FDA’s regulatory framework governing the
drug testing and approval process.
Aldes, supra note 54, at 463 (footnotes omitted).
166. For an excellent treatment of the Vioxx controversy with a focus on the overall U.S. and
EU regulatory processes for pharmaceuticals, see Thomas, supra note 58. Vioxx illustrates all
too vividly that, without meaningful regulatory reform, it may take many years of market use;
tremendous financial costs to consumers, taxpayers, and other payers; lost opportunities to
improve human health; and even the loss of many human lives before serious product
shortcomings are confronted. In a 2002 broadcast journalism documentary entitled Bitter
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its level of scrutiny, which has generated substantial drug sponsor demand for
specialized toxicology studies by CROs.167 In fact, Vioxx and related concerns
about FDA effectiveness inspired inquiry and generated corroborating reports
on deficiencies from the Government Accountability Office (“GAO”), the
Institutes of Medicine (“IOM”), and congressional hearings.168 These

Medicine: Pills, Profit, and the Public Health, supra note 141, Vioxx was challenged on many
levels—several years before its market recall. Nevertheless, the product remained on the market
at tremendous cost above over-the-counter alternatives such as Ibuprofen, only to be exposed and
pulled from the market in 2004. Thomas, supra note 58, at 366, 368.
167. Nagano, supra note 1. CROs are commercial service providers that meet both basic and
clinical research needs, and the business is burgeoning. Id. Unfortunately, guidance and
enforceable law-policy to protect human subjects has not been introduced in sync with this trend:
The globalization of medical research is, in effect, quickly outpacing the development of
internationally accepted ethical guidelines for the conduct of research. For many medical
researchers working in resource-poor countries, ethical decision-making is like sailing in
the days before modern navigation; one is never quite sure where one is, or in what
direction one is headed.
Daniel W. Fitzgerald & Angela Wasunna, Away from Exploitation and Towards Engagement: An
Ethical Compass for Medical Researchers Working in Resource-Poor Countries, 33 J.L. MED. &
ETHICS 559, 559 (2005); see also Malinowski, supra note 44, at 70–71 (offering several options
for dealing with the gap); Jennifer L. Gold & David M. Studdert, Clinical Trials Registries: A
Reform That Is Past Due, 33 J.L. MED. & ETHICS 811, 811 (2005) (supporting the establishment
of a conclusive registry for clinical trials conducted abroad); Joe Stephens, Where Profits and
Lives Hang in Balance, WASH. POST, Dec. 17, 2000, at A1 (discussing the lack of regulation and
oversight characteristic of trials in some foreign countries).
A sign of the trend: In August, Princeton, N.J.-based CovanceCVD, the largest U.S. CRO,
struck a deal with Eli Lilly to buy Lilly’s R&D labs in Indiana for $50 million. The deal
will transfer 260 Lilly employees to Covance. Lilly also guaranteed Covance a 10-year
business contract worth $1.6 billion.
Nagano, supra note 1.
168. Both the GAO and IOM have criticized the FDA’s performance regulating new drugs in
the marketplace and emphasized the need to make the clinical research data submitted for market
approval transparent to the public. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 5;
INST. OF MED., supra note 67, at 3. Neither Congress nor the FDA have addressed the possibility
that the drop-off in innovative new drug approvals and poor performance of many on the market
are an indication that the integrity of the entire forthcoming generation of biopharmaceuticals has
been jeopardized by law and policy that comprehensively integrated academia and industry
without shoring up the public nature of science. Michael J. Malinowski, Keynote Address: A
Discourse on the Public Nature of Research in Contemporary Life Science: A Law-Policy
Proposal to Promote the Public Nature of Science in an Era of Academia-Industry Integration, in
BIENNIAL REVIEW OF LAW, SCIENCE & TECHNOLOGY 1, 9–12 (2010). During the span of the
career of a single academic researcher, norms have shifted from industry independence,
collegiality, disclosure and sharing of materials and information, quick and unfettered
publication, and broad dissemination of information that invited meaningful scrutiny and rigorous
peer review to strong technology transfer administration within academic research institutions, no
communication without executed confidentiality and disclosure agreements and provisional
patent applications, no publication without sponsor preapproval, and no sharing of materials
without executed material transfer agreements. See id. at 9–19.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2012]

DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY?

397

questions about the sufficiency of drug regulation and overall agency
performance prompted FDA Commissioner Margaret Hamburg, when newly
appointed, to establish a task force with the mission of developing
recommendations to increase transparency of the Agency’s activities and
decision-making.169
Avandia illustrates a trend that accompanied modernization of the Agency
through the FDAMA: conditional market access with reliance upon postmarketing studies for safety and efficacy assurances.170 With the introduction
of user fees under the PDUFA171 and modernization through FDAMA,172 the
Agency has approved drugs based upon surrogate endpoints—indications that
the drug performs, rather than definitive proof—and conditioned upon followon clinical studies.173 Sixty-four drugs reached the market conditionally
between 1992 and 2008.174 According to the GAO, the FDA has allowed
drugs to stay on the market even when follow-up studies showed they did not
save lives.175 Although more than one-third of these conditional studies are
pending, the FDA never has pulled a drug from the market because of a failure
to do required follow-up about actual benefits—even when the information is

169. Press Release, U.S. Food & Drug Admin., FDA Forms Transparency Task Force (June
2, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm
163899.htm. In 2004, Congress considered measures to force public disclosure of clinical data
through the Internet to enable scrutiny by the medical and science communities, but then backed
away when some of the major pharmaceutical companies announced they would do so
voluntarily. See Ted Agres, Congress Wants Data to Be Free, DRUG DISCOVERY & DEV., Nov.
2004, at 14; Editorial, Hiding the Data on Drug Trials, N.Y. TIMES, June 1, 2005, at A20
(commenting on a government survey that “determined that three of the largest drug companies
[Merck, GlaxoSmithKline, and Pfizer] have effectively reneged on their pledges to list trials in a
federal database”); Tamsin Waghorn, Rattled Drug Giants Act Over Safety Concerns, EXPRESS,
Jan. 7, 2005, at 78.
170. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, §
130, 111 Stat. 2296, 2231–32 (codified at 21 U.S.C. 356b; 21 U.S.C. § 355a (2006)). The
Agency’s mission was expanded from ensuring efficacy and safety to including efficiency. See
supra note 66 and accompanying text.
171. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (codified
primarily at 21 U.S.C. § 379g–h). PDUFA, which was enacted with a five year sunset provision,
has been reauthorized three times. See supra note 66 (PDUFA II enacted in conjunction with
FDAMA in 1997); Public Health Security and Bioterrorism Preparedness and Response Act of
2002, Pub. L. No. 107-188, §§ 501–509, 116 Stat. 594, 687–694 (PDUFA III); Food and Drug
Administration Amendments Act of 2007, Pub. L. No. 110-85, §§ 101–109, 121 Stat. 823, 825–
842 (codified as amended in scattered sections of 21 U.S.C.) (authorizing PDUFA IV through
2012).
172. Food and Drug Administration Modernization Act of 1997, 111 Stat. 2296.
173. Evans, Seven Pillars, supra note 24, at 454 n.240, 478, 486.
174. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 74, at 15. For a critique of the FDA’s
post-market decision-making process, see U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67.
175. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 74, at 32–33.
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more than a decade overdue.176 This failure is consistent with GAO and IOM
declarations that the FDA’s performance post drug approval is substandard.177
The very integrity of contemporary drug science has been called into
question. Arguably, “government interventions are necessary to protect and
preserve the public nature of science, which is essential to shore up the
contemporary science enterprise.”178 Aggressive integration of academia and
industry has created a proliferation of conflicts of interest, and the public
nature of science—collegiality, communication, transparency, and
accountability—has shifted in the direction of secrecy.179 In the words of one
observer, “It has turned universities into commercial entities, created a
multibillion-dollar industry of technology transfer, and subsidized virtually
every biotechnology company and discovery of the past twenty-five years.”180
The science publications depended upon for scrutiny, accountability, and
human health assessment have also embraced commercialization—evident by
conflicts of interest controversies and the journals’ imposition of high cost
barriers to access their publications:181

176. Id. at 33. For example, Shire Laboratories failed to complete a study for ProAmatine, a
medication for low blood pressure, for more than thirteen years. Id. at 33–34.
177. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 18–36; INST. OF MED., supra
note 67, at 1.
178. Malinowski, supra note 168, at 23.
179. Id. at 13–19.
180. Lorelei Ritchie de Larena, The Price of Progress: Are Universities Adding to the Cost?,
43 HOUS. L. REV. 1373, 1375 (2007). For another evaluation of the Bayh-Dole Act, which gave
universities greater patent rights, see DAVID C. MOWERY ET AL., IVORY TOWER AND INDUSTRIAL
INNOVATION: UNIVERSITY-INDUSTRY TECHNOLOGY TRANSFER BEFORE AND AFTER THE BAYHDOLE ACT (2004).
181. Malinowski, supra note 168, at 16. Several of the most renowned science publications,
including the New England Journal of Medicine and Journal of the American Medical
Association (“JAMA”), have been involved in embarrassing conflicts of interest controversies.
See Linda A. Johnson, New England Journal of Medicine Admits Lapses in Ethics Policy, CHI.
SUN-TIMES, Feb. 24, 2000, at 21 (reporting that the “New England Journal of Medicine admitted
violating its financial conflict-of-interest policy 19 times over the last three years in its selection
of doctors to review new drug treatments”).
The primary guidance for conflict of interest management by medical journals is the
Uniform Requirements for Manuscripts Submitted to Biomedical Journals, a consensus
document issued and subsequently revised by the International Committee of Medical
Journal Editors (ICMJE) and allegedly utilized by more than 500 journals. See
International Committee of Medical Journal Editors, Uniform Requirements for
Manuscripts Submitted to Biomedical Journals, 277 JAMA 927, 927 (1997). . . . Despite
widespread utilization of the ICMJE requirements, according to a report published in the
April 2001 issue of Science and Engineering Ethics by Sheldon Krimsky and co-authors
from the University of California at Los Angeles, “[i]n reviewing 61,134 scholarly articles
published in 181 academic journals in 1997, researchers . . . found that just one-half of 1
percent detailed personal financial interests, including consulting arrangements,
honorariums, expert witness fees, company equity and stock, and patents.” Sheryl Gay
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The vast capacity to publish research and to share knowledge is tainted by
conflicts of interest which threaten the reliability and integrity of the peer
review process and, consequently, the underlying research. Governments,
professional societies, and most science journals have failed to introduce and
enforce the mechanisms necessary to manage conflicts of interest in an era of
aggressive commercialization with meaningful confidence.

Also, industry has directly increased its influence over government and the
general public substantially over the last few decades.182
PDUFA
legislation,183 direct interface between industry and the broader government
through extensive lobbying,184 and direct communication with the general
public through billions of dollars invested in marketing annually have raised
concerns and inspired calls for more regulation.185
III. LAW-POLICY ALCHEMY: A PROPOSAL TO CHANGE THE SCIENCE
STANDARD IN HUMAN CLINICAL RESEARCH FROM GOLD TO PLATINUM
The FDA science standard for drug approval and the law-policy
implementing it are, at best, dangerously dated—to the detriment of drug
development, the practice of medicine, and human health.186 Nevertheless, the
commercial interests vested in new drug development, domestic and
international, are too influential and too wedded to GD for an expansive break
from the past to be a realistic possibility in the foreseeable future.187 Under
PDUFA, which generates the salaries of more than 900 FDA reviewers
through the collection of user fees, industry has tremendous ongoing
negotiation leverage given the inclusion of five-year sunset provisions in each
PDUFA renewal coupled with two decades of FDA financial dependence for a
considerable portion of its new drug review operating budget.188
Arguably, wholly uprooting the entrenched science standard, even if this
were a viable option, would not be desirable given the approximately fifteenStolberg, Scientists Often Mum About Ties To Industry, N. Y. TIMES, Apr. 25, 2001, at
A17. Moreover, those disclosures all appeared in just one-third of the 181 journals. Id.
Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of AcademicIndustry Alliances, 8 WIDENER L. SYMP. J. 47, 59 n.57 (2001).
182. See Thomas, supra note 58, at 376.
183. The PDUFA legislation and user fee system are addressed supra notes 170–74 and
accompanying text.
184. Commentators have estimated that there are as many as six lobbyists working in
Washington, D.C. on behalf of the pharmaceutical sector for every member of Congress. Sharyl
Attkisson, Health Care Lobbyists’ Rise to Power, CBS NEWS (Oct. 29, 2009), http://www.cbs
news.com/stories/2009/10/20/cbsnews_investigates/main5403220.shtml; see also 20/20: Sick in
America: Whose Body is it Anyway? (ABC News television broadcast Sept. 14, 2007).
185. ANGELL, supra note 105, at 118–21; See Thomas, supra note 58, at 366.
186. See U.S. FOOD & DRUG ADMIN., supra note 141, at i.
187. See supra note 184 and accompanying text (noting the industry’s lobbying resources).
188. See supra note 171 for a discussion of PDUFA I–IV.
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year timeline to develop each innovative new drug and the transitional nature
of ongoing science in the drug development pipeline.189 Such a major change,
especially if forced through law-policy that imposes more clinical trial
obligations, could chill investment in pharmaceutical R&D, which is sorely
needed during this time of historically high drug development costs, product
disappointments, and economic challenges that extend well beyond the
biopharmaceutical sectors.190
Although drug development is evolving in the direction of precision
through genomics (genetic expression),191 proteomics (protein expression),192
and related fields, overall, the endeavor still remains too crude to adopt SSRD
as a substitute for traditional GD.193 As observed by the FDA’s Janet
Woodcock, an agency leader under several presidential administrations, both
Democratic and Republican, “At this time, medical practice is predicated on
observation. For example, we still collectively categorize lung cancer as we
did one hundred years ago. We still are not sophisticated. We don’t know
what the actual molecular cause of that particular cancer is in that particular
person because we don’t look for it.”194 However, the biopharmaceutical
sectors certainly have the resources and capabilities to rise to the occasion of a
higher standard in clinical research than traditional GD.195

189. See BIOTECHNOLOGY INDUS. ORG., supra note 132, at 38; BioBytes: The Biotech Drug
Delivery Timeline, BIOTECHNOLOGY INDUS. ORG., http://www.bio.org/content/biobytes-biotechdrug-delivery-timeline (last visited Dec. 29, 2011) (providing a short video discussing the drug
development process); Drug Discovery Timeline, PHRMA, http://www.phrma.org/media/multi
media/drug-discovery-timeline (last visited Dec. 29, 2011) (same).
190. Consider that when former President Clinton and former Prime Minister Tony Blair
made a statement on March 14, 2000, that was critical of biotechnology patenting, the sector
dropped by $100 billion over the next 24 hours. Malinowski, supra note 13, at 60 n.167.
191. See supra notes 124–125, 134 and accompanying text.
192. See generally Genomics Revolution, supra note 13 (discussing the advantages of
genomics, including protein expression).
193. Patient-Tailored Medicine Part One, supra note 13, at 35 (assessing that the advent of
personalized medicine is at least a decade in the future); Patient-Tailored Medicine Part Two,
supra note 13, at 42.
194. Woodcock, supra note 135, at 93. Sophisticated genetic screening capabilities exist, but
that is not the equivalent of them being commercially available. See Malinowski, supra note 13,
at 56–58. For example, in April 2010 scientists announced a screening technique that can predict
approximately three quarters of smokers who will develop lethal lung cancers. Joseph Hall,
Smokers’ Odds Just Got a Lot Better, TORONTO STAR, Apr. 8, 2010, at A1. Science researchers
also have developed a test that measures the expression of twenty-one genes to quantify the risk
of breast cancer recurrence and make better treatment decisions. BIOTECHNOLOGY INDUS. ORG.,
supra note 132, at 35. The National Institutes of Health is advancing testing in oncology through
The Cancer Genome Atlas, a project to map gene variations that cause cancer, spur its growth,
and cause therapeutic resistance. Id.
195. See BIOTECHNOLOGY INDUS. ORG., supra note 132, at 2. See also supra note 141 and
accompanying text. Visit the official sites of the industry’s trade organizations: the
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A meaningful, pragmatic transition is needed: SSRD should be introduced
as a complement or nested research methodology to GD to shift more
meaningful understanding of pharmaceuticals from clinical care (the delivery
of health care to patients) to clinical research; to lessen experimentation on
patients in the delivery of their care through physician off-label use, which is
removed from regulations to protect human subjects;196 and to infuse
responsiveness to the increasing precision enabled in both drug development
and the delivery of care by contemporary genetic science.197 “For biomedical

Biotechnology Industry Organization (“BIO”) at www.bio.org, and the Pharmaceutical Research
and Manufacturers of America (“PhRMA”) at www.PhRMA.org.
196. See supra notes 115–20 and accompanying text (describing the rise in off-label
prescribing). Protections for human subjects are afforded under the Common Rule triggered by
federal funding of research and FDA regulations imposed as a condition to engage in research
under its watch—to which off-label use of drugs does not apply. See 45 C.F.R. § 46.122 (2010);
21 C.F.R. § 50.1 (2010).
197. Cf. John F. Niblack, Toward a Structured National Program to Speed the Invention and
Development of New Technologies for Measuring the Progression of Chronic Diseases, in
BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, at xviii–
xxi (Gregory J. Downing ed., 2000) (describing the role of genomic technology in preventing and
treating chronic disease); Robert H. Glassman & Anthony Y. Sun, Biotechnology: Identifying
Advances from the Hype, 3 NATURE REVIEWS: DRUG DISCOVERY 177 (2004) (considering the
causes of slow developments in biotechnology and ways to increase biotechnology value
capture); David F. Horrobin, Modern Biomedical Research: An Internally Self-Consistent
Universe with Little Contact with Medical Reality?, 2 NATURE REVIEWS: DRUG DISCOVERY 151
(2003) (calling for a critical assessment of the use of in vitro and animal models to understand
human disease). As observed by the FDA,
Greater success along the critical path demands greater activity in a specific type of
scientific research that is directed at modernizing the product development process. Such
research—highly pragmatic and targeted in its focus on issues such as standards, methods,
clinical trial designs and biomarkers—is complementary to, and draws extensively from,
advances in the underlying basic sciences and new technologies. Without a concerted
effort to improve the critical path, it is likely that many important opportunities will be
missed and frustration with the slow pace and poor yield of traditional development
pathways will continue to escalate.
U.S. FOOD & DRUG ADMIN., supra note 141, at 29. As stated by a proponent of applying SSRD
in drug development research:
Research in biomedicine appears to rely on randomized parallel group clinical trial
designs and considers these trials the “gold standard” when determining treatment
effectiveness. However, large-scale trials contain inherent limitations in that they can be
expensive and time consuming. In addition, patients are unique and may not respond
similarly to various treatments, and in those instances a randomized clinical trial design
may be inappropriate. Guidelines are established from the averaged study findings, which
may not necessarily be applicable when evaluating suitable treatment options for
individuals. Specifically, patients treated in primary care settings may differ clinically
from patients in the clinical trial, the patient diversity in the clinical trial may not
generalize to certain patient populations, and the stringent trial criteria for accepting
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researchers, the best course for increasing scientific understanding of relevant
phenomena revolves around the utilization of a variety of methodological
designs, with the research question of interest determining the choice of the
design.”198 Although meaningful SSRD data could complicate GD trials and
lengthen the drug approval process, understanding pharmaceuticals much more
before they reach the market is sorely needed.199 Moreover, it is a cost that
could be contained through incremental implementation and potentially offset
through a reduction in the lost opportunities attributable to drug
underdevelopment. Although SSRD presumably would narrow the existing
opportunity to oversell by making new drugs more thoroughly understood
prior to their market entry, the extra data could raise the presently waning
confidence of providers and patients—a “one-two punch” of science. From a
regulatory perspective, infusing more specificity into the product approval
process, knowing much more about pharmaceuticals prior to putting them on
the market, and, consequently, restricting the familiar level of off-label use are
desirable and needed—and demanded increasingly by government policy
makers and the general public.200
The following discussion establishes the potential of SSRD to improve
drug development and health care delivery, with emphasis on the practicality
and feasibility of incorporating SSRD into human clinical research. After
identifying law-policy options, the Article emphasizes the use of positive
commercial incentives based upon enacted legislation that has succeeded in
getting desired human clinical trial research undertaken by industry—namely
the BPCA and the ODA, each of which is addressed in the following
discussion.
A.

SSRD’s Potential to Improve Drug Development and Delivery

Wait-and-see dependence on the medical profession to sort out the impact
of prescription medications on individuals, one patient at a time, in a trial-anderror manner, “exposes patients to potentially harmful drug interactions and

participants may not accurately reflect general patient populations. This is an important
consideration as the field of biomedicine strives to pursue cultural competency.
JANOSKY ET AL., supra note 6, at 81–82 (footnotes omitted).
198. JANOSKY ET AL., supra note 6, at 25.
199. See supra Part II (addressing drug underdevelopment, including the limited number of
drug targets used to treat all human ailments); infra Part III.C (describing the absence of
regulatory oversight of drugs in light of the current dependence on the medical community on offlabel drug experimentation).
200. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121
Stat. 823 (codified as amended in scattered sections of 21 U.S.C.) (authorizing fees that will go
toward expediting drug development and increasing post-market drug safety); U.S. FOOD &
DRUG ADMIN., supra note 141, at 11.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2012]

DRUG DEVELOPMENT—STUCK IN A STATE OF PUBERTY?

403

delays potentially effective or the ‘right’ treatment.”201 As recognized by Dr.
Janosky, an expert in SSRD, there is a strong parallel between SSRD and the
actual delivery of health care:
In a primary care setting, the patient generally exhibits symptoms and the
physician follows evidence-based or appropriate steps to treat these symptoms.
The physician evaluates the patient’s history, signs, symptoms, medical test
results, and examines the patient, and subsequently implements a treatment or
intervention if warranted. . . . In primary care settings, standardized procedures
are employed that include objective measurement of the outcomes, such as
systolic blood pressure measurements. These design and intervention
procedures are analogous to the standardized procedures used in single subject
research designs, such as testing the effectiveness of a medication over a
202
course of time.

SSRD, the very nature of which is close scrutiny of each of the individuals
under study,203 could improve decision-making during the clinical trial process
and actually increase flexibility in clinical research for drug development
because it presents an opportunity to tailor interventions for specific subjects
and to modify ineffective ones over the course of the period of study.204 A
major practical advantage of SSRD over GD is that “[i]t overcomes some of
the inherent limitations found in large-scale clinical trials, in that treatments
are tailored for unique individuals and can also be modified over time.”205
SSRD data could better enable sponsor decision-making for its GD
counterpart, thereby saving them from investing hundreds of millions of
dollars in the development and marketing of products like Vioxx, Avandia, and
Accutane, each of which has exposed their manufacturers to substantial
product liability and class action lawsuits.206 By addressing human variability
through SSRD, drug sponsors could cut back significantly on the time and
expense of human clinical trials that are required to put new drugs on the
market, both of which have risen significantly in recent years.207 Moreover,
there is an obvious ethics advantage in that many SSRD designs ensure that

201. Patient-Tailored Medicine Part One, supra note 13, at 28.
202. JANOSKY ET AL., supra note 6, at 81; see also Burke & Psaty, supra note 120, at 1684
(noting the individualized nature of clinical health care); Patient-Tailored Medicine Part One,
supra note 13, at 9 (same).
203. See supra Part I.B.
204. JANOSKY ET AL., supra note 6, at 81.
205. Id. at 82, 95 (“Single subject designs also provide greater flexibility for treatments, as
ineffective interventions can be modified over the period of study. Thus, single subject designs
should be considered when conducting research in biomedicine, as the methodology and
interventions can be tailored for specific individuals.” (footnotes omitted)).
206. For a thoughtful treatment of products liability in the context of pharmaceuticals, see
Patient-Tailored Medicine Part Two, supra note 13, at 21–36.
207. See supra notes 78–84 and accompanying text.
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each individual receives the treatment(s) and does not require denying patients
access to potential treatments to create a control—a standard component of
GD.208 SSRD could even enable research not practicable under GD.209 As
explained by Professor Janosky,
Specifically, at times it is difficult to find a large number of patients who have
unique demographics or suffer from rare diseases. Furthermore, large N
studies can be time consuming. One of the consequences of the time
consuming nature of large N research is the difficulty in studying public health
crises, for example. Additionally, the exorbitant financial costs of largesample research often limit who is able to conduct such projects, at times
risking an ethical dilemma with the linking of the researcher and the funder in
mutual vested interests in the results.
For example, funding from
pharmaceutical companies is often needed to conduct the multi-million dollar
210
research necessary for evaluating the same drugs those companies produce.

SSRD, with its emphasis on responsiveness to human variability, offers an
opportunity to identify genetic markers and to develop meaningful biomarker
screens during the human clinical trial process. Specifically, SSRD introduces
an opportunity to use the clinical trial process to develop a bouquet of
sophisticated genetic screens—for example, genetic tests that stratify patients
in the trials to discern those most prone to responsiveness and those at higher
risk for adverse events, and perfecting drug dosage on a person-by-person
basis.211 Genetic differences impact responses to pharmaceuticals, and at times
do so profoundly.212 Studies establish that enzyme variations in genes, with
thirty or more enzymes typically coded for each gene, may have a profound
impact on the rate that they are metabolized—a major consideration for what
constitutes safe and effective dosing for individual patients.213 A noted
illustration is the wide variation in patient reactions to asthma medications,

208. JANOSKY ET AL., supra note 6, at 27–28.
209. Id. at 28.
210. Id. For further discussion of financial conflicts of interest in the research setting, see
CTR. FOR HEALTH & PHARM. LAW & POLICY, supra note 81.
211. While innovative new drug returns on the HGP have been disappointing thus far,
genomics has introduced a new dimension of research opportunity and is impacting clinical
medicine. See Robert Goldberg & Peter Pitts, Prescription for Progress: The Critical Path to
Drug Development 1, 7–9 (21st Century FDA Task Force Working Paper, 2006), available at
http://www.manhattan-institute.org/pdf/CMP_FDA_Task_Force.pdf; Patient-Tailored Medicine
Part One, supra note 13, at 8–9.
212. See Patient-Tailored Medicine Part One, supra note 13, at 7, 16–17.
213. PERSONALIZED MED. COAL., THE CASE FOR PERSONALIZED MEDICINE 4 (2006),
available
at
http://www.cspo.org/outreach/md/docs/TheCaseforPersonalizedMedicine.pdf;
Patient-Tailored Medicine Part One, supra note 13, at 16–17.
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some of which studies have attributed to identified differences in genetic
makeup.214
B.

The Feasibility of SSRD in Drug Development—Precedent and Practice

Several trends suggest that drug sponsors should expect more scrutiny and
demands for accountability from regulators, the medical community, and the
general public: rising health care finance pressures, federal and state, domestic
and international; increased transparency of market performance and market
behavior through internet communication, including organized observation
through patient and consumer protection groups; and pressure on the FDA to
increase post-marketing regulation requirements and general enforcement.215
SSRD could prove a means to meet and quell these pressures, and
implementation is practicable: there is precedent for the use of SSRD in human
clinical research to advance health care, albeit almost entirely outside of the
context of biopharmaceutical development.216
Extensive SSRD human clinical research has been done in applied
behavior analysis and education,217 and “[n]umerous studies have highlighted
the importance of the single subject design paradigm in primary care.”218
Some especially notable disease-related group accomplishments utilizing
SSRD include a large portion of the research studying treatments for aphasic
patients (loss of the ability to articulate ideas or comprehend language due to
brain damage from injury or disease), attention deficit hyperactivity disorder
(“ADHD”), and diabetes.219 Many SSRD studies in the primary care setting
have been premised upon raising the predictability of responsiveness to
stimulant medications at various dosages, including an ambitious collective
assessment study carried out in Australia more than two decades ago. As
summarized by Professor Janosky,
[I]n the 1980s, McMaster University designed a service for community and
academic physicians to facilitate the planning and conduction of single subject
(N-of-1) trials. The effectiveness of the trials was evaluated by the physicians’
management plans and confidence levels in the plans both prior to and
following trials. A total of 57 single subject trials were completed, with 50
trials providing a definite clinical answer and 15 resulting in the physician

214. Lyle J. Palmer et al., Pharmacogenetics of Asthma, 165 AM. J. RESPIRATORY &
CRITICAL CARE MED. 861, 861 (2002); Alix Weisfeld, Comment, How Much Intellectual
Property Protection Do the Newest (and Coolest) Biotechnologies Get Internationally?, 6 CHI. J.
INT’L L. 833, 835 (2006).
215. See supra notes 160, 168, and 200 and accompanying text.
216. Professor Janosky provides a full annotated bibliography of SSRD articles recently
published in PsycInfo, MEDLINE, and PubMed. JANOSKY ET AL., supra note 6, at 97–114.
217. See supra note 7 and accompanying text.
218. JANOSKY ET AL., supra note 6, at 83.
219. Id. at 82–84.
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altering patient treatment. In those 15 trials resulting in treatment adjustment,
11 trials lead to physicians discontinuing the medication therapy they planned
to administer indefinitely. Trials that were not completed generally stemmed
from patient’ or physician’ noncompliance or patient’ concurrent illness
220
[sic].
Based upon these results reported by the collaborative team at McMaster
University, single subject trials afford important opportunities for application
221
in biomedicine, including directly improving patient clinical care.

SSRD experience in human clinical trials and in the primary care context over
decades could be infused into drug development readily, creatively, and with
flexibility, as demonstrated by Professor Gina Green:
Unlike between-groups studies, single-case studies can be conducted in typical
service settings like schools, treatment centers, hospitals clinics, and homes.
Their focus on the development of individual behavior and their flexibility
makes these methods especially well-suited for studying treatments for [autism
spectrum disorders], given the large individual differences among people with
those diagnoses. Single-case research methods also afford a means for
practitioners as well as researchers to evaluate the effects of many types of
treatments—behavioral, educational, medical, or combinations—with
222
scientific rigor.

A report issued by the IOM in 2001, which provided initial guidelines for
small clinical trials, is an affirmation of the feasibility and potential utility of
SSRD in drug development.223 The report recognized the potential utility of
these trials for a portfolio of situations, including rare diseases, unique study
populations, individually tailored therapies, isolated environments (for
example, health care in rural areas), emergency situations, and public health
urgency.224
An SSRD component to clinical trials for drug development would
introduce several potential benefits, in addition to raising fundamental
understanding about new drugs during the pre-market clinical research stage.
The size and costs of GD trials have increased immensely in concert with the
proliferation of the genetic sciences and associated precision—which by its
very nature demands increased attention to human variability.225 The GD
approach is demonstrating decision-making confusion and clinical trial

220. Id. at 82 (footnotes omitted).
221. Id. at 1.
222. Green, supra note 6, at 79.
223. INST. OF MED., SMALL CLINICAL TRIALS: ISSUES AND CHALLENGES 57–59 (Charles H.
Evans, Jr. & Suzanne T. Ildstad eds., 2001).
224. Id. at 16 tbl.1-2; see also JANOSKY ET AL., supra note 6, at 2 (discussing the IOM Report
and elaborating on SSRD methodology).
225. See supra notes 78–79 and accompanying text.
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failures.226 As observed in an April 2010 report issued by the Institute of
Medicine, approximately forty percent of all advanced clinical trials sponsored
by the National Cancer Institute, organized under the GD gold standard for the
most part, are never completed—resulting in a waste of money, effort, and lost
opportunities to improve human health and reap financial returns.227
An obvious primary question for implementation of SSRD is, given
industry’s entrenched commitment to GD, how to use SSRD and GD together
in drug development. Johnston and Pennypacker, authors of a heavily-cited
text on behavioral research that compares and contrasts SSRD and GD,
propose that, where both are used, SSRD should be utilized to graph and check
data for each subject as a quality control on GD reliance on inferential
statistical techniques and interpretation to generate and explain data.228 In fact,
they believe that all data should be subjected to SSRD scrutiny before it even
is eligible for use in GD.229 Their primary concern is that group data risks
obscuring individual patterns of responding:
[T]he more an analytical procedure changes the investigator’s picture of the
subject’s behavior as it actually happened, the greater the risk that the
analytical procedure may exert more control over interpretations than do the
data. . . .
A related guideline may be stated as follows: The more an investigator has
to change the data to see something important, the greater the risk that the
230
result is not that important or, perhaps, not even there.

To begin the transition into utilization of SSRD in biopharmaceutical
R&D,231 one option is to pursue running SSRD and GD trials in parallel and
throughout Phases I–III of the pre-market human clinical trial process.232
Incorporating the Johnston and Pennypacker approach, SSRD trials could be
started in advance and used to shape GD trials, and then as a quality control

226. Over the last five years, Phase III trials have expanded from 3000 to 20,000 subjects and
their cost has doubled to reach $100 million. See supra note 79 and accompanying text.
227. INST. OF MED., A NATIONAL CANCER CLINICAL TRIALS SYSTEM FOR THE 21ST
CENTURY 29 (2010); Opinion, Faltering Cancer Trials, N.Y. TIMES, Apr. 25, 2010, at A11.
228. JOHNSTON & PENNYPACKER, STRATEGIES AND TACTICS, supra note 7, at 304. Johnston
and Pennypacker propose that researchers “not create group data until they have already
conducted a thorough analysis of the individual data that is included.” Id.
229. Id. As explained by Johnston and Pennypacker, “One reason for this rule is that group
data obscures individual patterns of responding. Regardless of whether the collated data present
an interesting or expected picture, they do not necessarily represent what can be seen by looking
at the records from each individual subject.” Id.
230. Id. at 298.
231. Imposing SSRD as a substitute for GD is not practicable or even desirable at this time.
See supra notes 189–90 and accompanying text.
232. See supra Part I.A (discussing the phases of the clinical trial process).
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throughout their duration.233 Another possible approach would be to use
SSRD more intensely in a focused capacity—perhaps for specific trials,
specific patient subpopulations, or for specific treatments, such as those for
rare patient populations in conjunction with the Orphan Drug Act.234
Specifically, “single subject designs may be nested within larger clinical trials
to increase compliance and answer more detailed questions. Single subject
designs are particularly useful for answering questions regarding rare diseases,
side effects, unique populations, emergency situations, and isolated
environments, in which between-group designs would be unfeasible or
impractical.”235
Another option, and one that could be applied in conjunction with the
others, would be to introduce SSRD services to assist physicians with market
use of prescription drugs as an extension of Phase IV trials—an application
strongly supported by the McMaster University study and ample primary care
applications.236 In summary,
Research supports the effectiveness of the single subject design, from studying
treatments for rare patient populations to providing N-of-1 trial services in
assisting physicians. The single subject design is an innovative addition to the
arsenal of available methodologies for primary care physicians, biomedical
students, residents, medical research faculty, clinical practitioners, among
others. Consistent with the NIH Roadmap Initiative, increasing awareness of
the utility in the single subject design could enhance treatment approach and
237
evaluation both in biomedical research and primary care settings.

233. See supra notes 228–30 and accompanying text.
234. See INST. OF MED., supra note 227, at 99 (describing a new strategy of using small
“targeted trial designs”); JANOSKY ET AL., supra note 6, at 93–95 (describing the use of SSRD for
a patient study involving a forty-two-year-old mixed race male with elevated blood pressure).
“Treatments are often unavailable for unique patient populations or rare disorders, and
researchers are left uncertain what designs or tools to use when implementing treatments.” Id. at
82.
235. JANOSKY ET AL., supra note 6, at 28–29 (footnotes omitted).
236. See id. at 82. “This methodology is also particularly suited for primary care practicebased research, where practitioners can tailor individualized treatments to improve outcomes.”
Id. at 29.
Tsapas and Matthews discussed that N-of-1 trials can be an optimal approach when
treating chronic diseases such as diabetes mellitus, which frequently rely on clinical
judgment and arbitrary criteria. The authors stated that guidelines for treating diabetes
have been criticized as being unreliable, as algorithms are generally established from
“clinical judgment and experience.” Single subject designs take into account the
uniqueness of the individual, rather than using a standardized treatment that may not be
effective for all diabetics.
Id. at 83 (footnote omitted).
237. Id. at 95. For documentation of the use of SSRD in biomedicine, see JANOSKY ET AL.,
supra note 6, at 97–114.
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C. Law-Policy Catalysts to Turn Gold into Platinum
Although “there is substantial proof that the current method of creating
medicines for the general public is problematic and could prevent effective
treatments from reaching the marketplace”,238 voluntary uptake of SSRD by
drug developers is unlikely. They are inclined to resist the official addition of
SSRD into the regulatory process for the same reason they have been slow to
introduce pharmacogenomics data (R&D based upon genetic expression239) in
their applications in spite of FDA encouragement—fear that it will be used
against them to limit their market reach. The FDA has issued voluntary
guidelines to promote submission of pharmacogenomics data which, in sync
with SSRD, innately involves closer individual patient scrutiny—including at
the genetic and molecular levels—and more extensive patient-centered data
compilation during the clinical trial process.240 Unfortunately, the guidelines

238. Patient-Tailored Medicine Part One, supra note 13, at 5.
239. See supra Part II.B.
240. Press Release, U.S. Food & Drug Admin., FDA Works to Speed the Advent of New,
More Effective Personalized Medicine (Mar. 22, 2005), available at http://www.fda.gov/News
Events/Newsroom/PressAnnouncements/2005/ucm108423.htm. As stated by the FDA,
This guidance is intended to facilitate scientific progress in the field of
pharmacogenomics and to facilitate the use of pharmacogenomic data in drug
development.
The guidance provides recommendations to sponsors holding
investigational new drug applications (INDs), new drug applications (NDAs), and
biologics license applications (BLAs) on (1) when to submit pharmacogenomic data to the
Agency during the drug or biological drug product development and review processes, (2)
what format and content to provide for submissions, and (3) how and when the data will
be used in regulatory decision making.
U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: PHARMACOGENOMIC DATA
SUBMISSIONS 1 (2005), available at http://www.fda.gov/downloads/RegulatoryInformation/Guid
ances/UCM126957.pdf (footnote omitted) [hereinafter U.S. FOOD & DRUG ADMIN., GUIDANCE].
For discussion of the clinical applications of pharmacogenomics and use of it to tailor therapies,
see Pharmacogenomics and Its Role in Drug Safety, FDA DRUG SAFETY NEWSL. (U.S. Food &
Drug Admin, Wash., D.C.), Winter 2008, at 24, available at http://www.fda.gov/downloads/
Drugs/DrugSafety/DrugSafetyNewsletter/ucm109169.pdf.
The FDA and the European
Medicines Agency (“EMEA”) have promoted the voluntary submission of genomic data jointly.
U.S. FOOD & DRUG ADMIN. & EUR. MEDS. AGENCY, GUIDING PRINCIPLES: PROCESSING JOINT
FDA EMEA VOLUNTARY GENOMIC DATA SUBMISSIONS WITHIN THE FRAMEWORK OF THE
CONFIDENTIALITY ARRANGEMENT (2006), available at http://www.fda.gov/downloads/Drugs/Sci
enceResearch/ResearchAreas/Pharmacogenetics/ucm085378.pdf; Federico Goodsaid, U.S. Food
& Drug Admin., Joint USFDA-EU Pharmacogenomic Initiatives (2006), available at
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm119097.pdf (presentation
on joint FDA-EU pharmacogenomic initiatives). To implement the guidelines and develop
related policy and standards, the FDA created the Interdisciplinary Pharmacogenomic Review
Group (“IPRG”). See CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG
ADMIN., MANUAL OF POLICIES AND PROCEDURES 4180.2: MANAGEMENT OF THE
INTERDISCIPLINARY PHARMACOGENOMICS REVIEW GROUP (IPRG) (2005), available at
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/StaffPoliciesandProcedures/
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have not overcome industry fear that genetic specification will break down
disease groups and restrict market reach through narrower approvals, more
defined product labels, reimbursement limitations, and less physician
discretion to use these pharmaceuticals off label. As explained by Dr.
Woodcock,
The primary policy problem right now is that most of these genetic tests are
not being evaluated in clinical studies, and they are not being seen by the
regulatory agencies. Application in the official drug development regulatory
process is stymied by concern about how these tests will be used by the
marketing application reviewers. This could present a real lost opportunity for
241
any person who wants to take medicine in the foreseeable future.

Even when pharmacogenomics data make it onto drug labels,242 the underlying
sponsor data released is limited, and the medical community often lacks the
knowledge to make efficient use of it.243
A thoughtful law-policy intervention beyond voluntary guidelines is
essential to add a meaningful SSRD component to drug development. Using
the regulatory process to attempt to impose commercial uses on new drug
candidates or specific types of human clinical trials on drug developers would
invite allegations of undue impediment on the commercial freedom that is the
touchstone of our private market system and introduce susceptibility to legal

ucm073574.pdf (setting out the charter for and duties of the IPRG). The FDA also has issued a
decision tree for genomic data submission. U.S. FOOD & DRUG ADMIN., GUIDANCE, supra, at 19.
241. Woodcock, supra note 135, at 93.
242. Although 121 new drug labels contain pharmacogenomic information with sixty-nine of
them referring to human genomic biomarkers, more than sixty-two percent of those with human
genomic information contain information related to drug metabolism and a large portion of the
rest is associated with cancer treatments. Felix W. Frueh et al., Pharmacogenomic Biomarker
Information in Drug Labels Approved by the United States Food and Drug Administration:
Prevalence of Related Drug Use, 28 PHARMACOTHERAPY 992, 994–95 (2008). A noted example
is the association between over expression of the genetic variance Her-2/neu and the breast cancer
drug Herceptin. See generally BAZELL, supra note 138 (describing this association in depth).
Experience to date suggests that drug sponsors’ fear that pharmacogenomics data in the
regulatory process will splinter their markets is not fully grounded given physician discretion and
inclination to use drugs off label, including in combination with other drugs. For example,
though Herceptin was developed to treat a very specific form of aggressive breast cancer
associated with over expression of the protein HER2, physicians have used it off label to treat
others with some success. In fact, in combination with Taxol, Herceptin has even been
discovered to treat prostate cancer. Herceptin and Taxol Combination Looks Promising for
Prostate Cancer, PSA RISING MAG.(Nov. 3, 1999), http://www.psa-rising.com/medicalpike/her
ceptintaxol.htm.
243. Kelly C. Lee et al., Pharmacogenomics: Bridging the Gap Between Science and
Practice, 50 J. AM. PHARM. ASSOC. e1, e2 (2010).
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challenges.244 The drug development regulatory regime embodies deference to
commercial free speech, proprietary interests, profit incentives, and the
discretion to practice medicine—as the FDA has been reminded by Congress
and through several legal challenges during the genomics revolution. For
example, the House Report that accompanied FDAMA expressly states that
“the FDA has no authority to regulate how physicians prescribe approved
drugs in the context of their medical practice. Physicians prescribing off-label
uses of approved drugs is not within the jurisdiction of the FDA.”245 As for
legal challenges, in 2000 the U.S. Court of Appeals for the District of
Columbia dismissed a challenge to FDAMA provisions addressing
manufacturer promotion of off-label use that claimed the provisions imposed
an undue burden on commercial free speech in violation of the First
Amendment.246 However, the Court based its decision on the fact that the
parties reached agreement that there was no longer an issue after the FDA
changed its stance.247
Perhaps the most vivid recent illustration of the limits of agency authority
to force studies on drug sponsors is the FDA’s attempt to fill the vacuum of
pediatric studies for pharmaceuticals known to be prescribed to children.248 In
244. See, e.g., Ass’n of Am. Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204,
217–18 (D.D.C. 2002); infra notes 248–61 and accompanying text (challenging FDA rules
proposing mandatory pediatric trials).
245. H.R. REP. NO. 105-310, at 60 (1997).
246. See Wash. Legal Found. v. Henney, 202 F.3d 331, 336–37 (D.C. Cir. 2000). At issue in
the case were “the FDA’s and Congress’ attempts to regulate two . . . promotional strategies:
manufacturer dissemination to physicians of independent medical and scientific publications
concerning the off-label uses of their products” (referred to as “enduring materials”), “and
manufacturer support for Continuing Medical Education (CME) programs for doctors that focus
on off-label uses.” Id. at 332–33.
247. Id. at 336.
248. While it is a common practice for physicians to prescribe to children pharmaceuticals
only approved for adult use, by doing so, they can expose children to various hazards. Children
may be given an ineffective dose or an overdose, and they face an increased risk of side effects.
Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and
Biological Products in Pediatric Patients, 62 Fed. Reg. 43,900, 43,901 (Aug. 15, 1997) (codified
at 21 C.F.R. pts. 201, 312, 314, 601). This happens because:
Correct pediatric dosing cannot necessarily be extrapolated from adult dosing information
using an equivalence based either on weight . . . or body surface area . . . . Potentially
significant differences in pharmacokinetics may alter a drug’s effect in pediatric patients.
The effects of growth and maturation of various organs, maturation of the immune
system, alterations in metabolism throughout infancy and childhood, changes in body
proportions, and other developmental changes may result in significant differences in the
doses needed by pediatric patients and adults.
Id. Faced with insufficient information about a new medication, pediatricians often opt to
prescribe their young patients older, less effective, but well-tested medication—as opposed to
newer, more effective medication that has not been subjected to rigorous study on pediatric
populations. Id. at 43,900. This practice keeps children from benefitting from state-of-the-art
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fact, even today, pediatric data is insufficient, at times wholly lacking, for twothirds of prescription drugs.249 A 1994 study reported that six of the ten drugs
most commonly prescribed to children had inadequate pediatric labeling,250
which inspired the FDA to issue a rule and to introduce a voluntary, incentivebased program to promote pediatric testing and labeling.251 The tone during
this time, under David Kessler who was the FDA Commissioner from 1990 to
1997, was administrative caution:
I need to acknowledge the limits of FDA’s authority. It is our job to review
drug applications for the indications suggested by the manufacturer. We do
not have the authority to require manufacturers to seek approval for indications
which they have not studied. Thus, as a matter of law, if an application
252
contains indications only for adults, we’re stuck.

To address this dearth of pediatric data even for drugs prescribed to
children routinely, Congress codified a voluntary, incentive-based five-year
program through a pediatric exclusivity provision in FDAMA.253 This
program granted drug manufacturers six months of market exclusivity for their
products—as opposed to just extending intellectual property rights—as an
incentive for conducting pediatric studies.254 The FDA then went further and
issued a “Pediatric Rule” in 1998 that mandated pediatric testing—both for
drug candidates and those already approved for market use.255 The FDA was

medication. See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of
New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632, 66,632 (Dec. 2,
1998) (codified at 21 C.F.R. pts. 201, 312, 314, 601). Ironically, the status of children as a
“protected group” under federal regulations to protect human subjects contributes to their
exclusion as a study focus in clinical research. See 45 C.F.R. §§ 46.401–.409 (2010) (setting out
the restrictions on research involving children).
249. See supra note 21–22 and accompanying text; Carolina Martinez-Castaldi et al., Child
Versus Adult Research: The Gap in High Quality Study Design, 122 PEDIATRICS 52, 52 (2008).
250. U.S. FOOD & DRUG ADMIN., THE PEDIATRIC EXCLUSIVITY PROVISION: JANUARY 2001
STATUS REPORT TO CONGRESS, at iii (2001).
251. See Specific Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of “Pediatric Use” Subsection in the Labeling, 59 Fed. Reg. 64,240 (Dec. 13,
1994) (codified at 21 C.F.R. pt. 201).
252. Ass’n of Am. Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 218 (D.D.C.
2002) (quoting David Kessler, FDA Comm’r, Address to the American Academy of Pediatrics
(Oct. 14, 1992)).
253. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 111,
111 Stat. 2296, 2305–09 (codified at 21 U.S.C. § 355a (2006)).
254. Id.; 21 U.S.C. § 355a(b)–(c) (2006). The FDA interpreted the provision broadly and
provided the six-month extension to all drugs derived from the active moiety put under pediatric
study. U.S. FOOD & DRUG ADMIN., supra note 250, at 7.
255. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New
Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632 (Dec. 2, 1998) (codified
at 21 C.F.R. pts. 201, 312, 314, 601).
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sued successfully under the Administrative Procedure Act256 with claims that
promulgation of the Pediatric Rule was arbitrary and capricious and exceeded
the FDA’s authority.257 The voluntary program worked but was only
moderately successful. As of April 2001, the FDA had issued a mere 188
written requests covering 155 drugs already on the market and just thirty-three
new drugs not yet approved.258 “As of April 1, 2001, only 28 drugs had been
granted periods of exclusivity.”259 Most of these drugs did experience a
labeling change of some degree to address pediatrics, but, according to an
article published in 2001, only 37.5 percent constituted a significant change in
safety or dosing.260 By discussions in 2001 to reauthorize the voluntary
program, only twenty-five percent of drugs had been studied in children—just
a five percent increase from the 1994 statistic.261
While the litigation against the FDA rule was pending and the FDAMA
voluntary program approached its January 1, 2002, sunset,262 Congress
intervened with the Best Pharmaceuticals for Children Act.263 BPCA
reinstated the FDAMA voluntary program for pediatric testing with the
incentive of six months of market exclusivity and then went further by
empowering the FDA to step over manufacturer resistance and get pediatric
trials done by third parties through the National Institutes of Health or with
funding from a federal trust.264 BPCA also provided a basis to strike the
FDA’s Pediatric Rule.265 Regarding the BPCA’s effectiveness, critics have

256. 5 U.S.C. §§ 701–706 (2006).
257. Ass’n of Am. Physicians and Surgeons, 226 F. Supp. 2d at 222.
258. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-01-705T, PEDIATRIC DRUG RESEARCH:
SUBSTANTIAL INCREASE IN STUDIES OF DRUGS FOR CHILDREN, BUT SOME CHALLENGES
REMAIN 4 (2001). By September 30, 2002, the FDA had issued a total of 256 written requests.
Michelle Meadows, Drug Research and Children, FDA CONSUMER, Jan.–Feb. 2003, at 12, 15.
For information about the Act, visit the official Internet site at Best Pharmaceuticals for Children
Act, NAT’L INSTS. HEALTH, http://bpca.nichd.nih.gov/ (last modified Dec. 13, 2011).
259. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 258, at 2.
260. William Rodriquez et al., Adverse Drug Events in Children: The U.S. Food and Drug
Administration Perspective, 62 CURRENT THERAPEUTIC RES. 711, 718 (2001).
261. S. REP. NO. 107-79, at 1–2 (2001).
262. 21 U.S.C. § 355a(j) (2000).
263. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002)
(codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.); see H.R. REP. NO. 107277, at 14 (2001) (explaining that while the incentive had been successful, it was not adequate to
address the need for studies in certain drugs such as those with no patent protection or those for
neonates); S. REP. NO. 107-79, at 2 (2001) (noting the success of the 1997 legislation as well as
the need to augment its provisions).
264. See 42 U.S.C. § 284m(a), (b) (2006).
265. In the words of the court, “After examining: (1) specific provisions of the FDCA, as well
as the Act’s broader context; (2) the legislative history of the BPCA; and (3) the conflict between
the BPCA and Pediatric Rule, this court concludes that Congress has directly spoken to the issue
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pointed out that the BPCA approach shifted considerable drug development
cost from manufacturers to taxpayers.266 Nevertheless, as of March 2004,
pharmaceutical manufacturers had issued 346 requests to evaluate prescription
drugs for pediatric use, ninety-seven drugs were granted six months of
exclusivity, and new labels were approved for seventy.267 As of 2008, 145
drugs had been issued exclusivity.268
Another illustration of the success of Congress and the FDA to utilize
positive commercial incentives to get desired clinical research undertaken in
drug development is the Orphan Drug Act. ODA is a rewards-based program
that makes it commercially viable to develop drugs for small groups of patients
through tax incentives, a seven-year period of market exclusivity, and other
benefits.269 The targeted research is being done: some 350 orphan drugs have
been approved in the U.S. market alone, and the program has been replicated
by other countries.270 Orphan drug filings have increased, especially
submissions from multinational pharmaceutical sponsors.
There is
considerable overlap between the ODA methodology and suggestions from
NIH and others to incorporate small clinical trials and SSRD into drug
development with an initial focus on small, discernible patient groups.
The effectiveness of commercial incentives to get desired clinical research
done has been demonstrated through ODA and BPCA, as has the

here and has precluded the FDA’s jurisdiction to promulgate the Pediatric Rule.” Ass’n of Am.
Physicians and Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 212 (D.D.C. 2002).
266. Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Children Act of 2002:
The Rise of the Voluntary Incentive Structure and Congressional Refusal to Require Pediatric
Testing, 40 HARV. J. ON LEGIS. 133, 134 (2003). For example, BPCA is costly:
While the BPCA is a strong step forward for children’s health, it comes at a significant
price. The six-month patent extensions cost consumers hundreds of millions of dollars
because of the delay in cheaper, generic drugs reaching the market. In addition to the
patent extensions, taxpayers will fund the drug studies that manufacturers refuse to
conduct, which average about $3.87 million per drug. For fiscal year 2002, Congress
appropriated $200 million to that end.
Id. (citing PUB. CITIZEN CONGRESS WATCH, PATENTLY OFFENSIVE: CONGRESS SET TO EXTEND
MONOPOLY PATENTS FOR CIPRO AND OTHER DRUGS 2 (2001), available at http://www.citizen.
org/documents/ACF34F.pdf).
267. Leslie Kushner, Incentivizing Postmarketing Pharmaceutical Product Safety Testing
with Extension of Exclusivity Periods, 19 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 519, 547–
48 (2009).
268. “As of Feb. 19, 2008, 145 drugs have been granted pediatric exclusivity.” Id. at 548
n.160.
269. Orphan Drug Act, Pub. L. No. 97-414, §§ 2, 4, 96 Stat. 2049, 2050–51, 2053–56 (1983)
(codified as amended at 21 U.S.C. § 360cc; 26 U.S.C. 45C (2006)); Mark D. Shtilerman,
Pharmaceutical Inventions: A Proposal for Risk-Sensitive Rewards, 46 IDEA 337, 342–43
(2006).
270. Orphan Drug Designation (ODD) Information, CLINUVEL, http://www.clinuvel.com/
pharmaceutical-regulation/orphan-drugs (last visited Dec. 29, 2011).
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ineffectiveness of soft incentives such as voluntary guidelines and the
susceptibility of FDA mandates to legal challenge. To implement SSRD into
drug development as quickly, effectively, and pragmatically as possible,
Congress and the FDA should build upon what has worked and an opportunity
introduced by a new government initiative—introduction of a federal research
center with the specific mission of helping industry overcome drug
development difficulties. Given the commonality between ODA—small,
distinguishable disease groups—and SSRD, ODA should be modified to favor
utilization of SSRD in program qualification and provide additional incentives
for its use, including additional tax incentives, additional reviewer support and
responsiveness, and an additional extension (at least one year, to make the total
exclusivity eight years) of market exclusivity for approved products that
complete SSRD studies. The FDA would have the discretion, as it does with
the base ODA program, to set criteria and determine eligibility—meaning the
Agency could experiment with SSRD to assess its efficacy in varied
applications.
For drug development beyond the small disease groups that qualify for
ODA status, Congress and the FDA should draw heavily from BPCA—
perhaps in a manner that, in addition to promoting SSRD overall, particularly
favors use of SSRD in pediatric studies and studies of other distinguishable
patient and disease groups to make up for the relative dearth of data over the
years. This approach would be closely consistent with the suggestions of
SSRD experts in disciplines that have embraced the approach, including
professors Green, Janosky, Johnston, and Pennypacker.271 SSRD studies
should be solicited with the incentive of at least six months of additional
market exclusivity for resulting products (pediatric studies with SSRD would
be rewarded with a year or more of product exclusivity), and Congress should
create a separate trust fund to enable the FDA to undertake these studies when
industry sponsors refuse. The fund should be established to direct the FDA to
include post-marketing (Phase IV) studies with primary care physicians on
both new and existing drugs to assist physicians with market use—along the
lines of the McMaster University study and suggestions of Dr. Janosky.272
Both the IOM and GAO have determined that the FDA does a grossly
insufficient job once pharmaceuticals reach the market and recent experience
with the disappointment of approved drugs confirms, suggesting that SSRD
studies, consistent with the practice of medicine, could make a substantial
contribution.273 An SSRD fund would impose a cost on taxpayers—a major

271. See supra Part III.B.
272. See supra note 220–22 and accompanying text.
273. See U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 67, at 18; INST. OF MED., supra
note 67, at 1.
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criticism of BPCA.274 Nevertheless, the state of drug development, new drug
disappointments, the potential of SSRD coupled with genetic precision to
improve drug development and benefit health care, the need to lessen
dependence on years of physician off-label use for meaningful understanding
of new drugs, consumption of government regulatory resources for this
disappointing return, and lost product opportunities for sectors that are a major
presence in our economy suggest that taxpayer investment in such a fund
would be more than justified—especially given the amount of funding taken
from industry in user fees to cover FDA operations. The federal government
appears to have recognized as much through establishment of a billion dollar
center to help industry create new drugs, headed by Dr. Francis Collins who
led the U.S. government HGP effort and now is Director of NIH.275
This center to assist drug development also should make SSRD a priority.
Although the Center is focused primarily on basic research—for example, to
use its state-of-the-art robotic screening capabilities to identify chemicals that
influence enzymes—and animal studies, its mission also includes starting
human trials.276 The center should broaden its clinical research vision and
include SSRD. The transition into clinical research in drug development
involves a substantial increase of industry investment—money, research, and
opportunity. Contingent upon the outcome of research, investment correlates
with industry commitment—meaning an inclination to want to work with the
center to resurrect troubled drug development efforts that hold market
potential. The center, preferably working in conjunction with the FDA, could
infuse SSRD to salvage developed drug R&D undertakings representing
substantial time and research investments and financial investments of tens, if
not hundreds, of millions of dollars. The Center’s involvement in just Phase I
trials could make significant contributions.277
CONCLUSION
The so-called gold standard for human clinical research in drug
development, GD, no longer glitters—to the extent it ever really did. The costs
of relying too heavily on GD are self-evident, including a significant decline in
new drug approvals in spite of historic investment and resources such as the
map of the human genome, drug disappointments such as Vioxx and Avandia
that have threatened the lives of the patients taking them and generated large

274. See supra note 265.
275. Harris, supra note 2.
276. Id.
277. See Aldes, supra note 54, at 464 (“Part of this oversight involves accounting for changes
in medicine and trial design both of which affect drug testing. As such, the FDA must
acknowledge when changes occur, and subsequently modify protocols and regulations that
govern the affected clinical trials.” (footnote omitted)).
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class action law suits, and dwindling faith in the FDA as evident in the passage
of the FDAAA in 2007 as well as the GAO and IOM reports issued in 2006.278
The crude science past in drug development, which may have justified
reliance on GD, no longer should control the genetics present and future of
human clinical research in biopharmaceutical R&D and FDA market approval.
Genetics is increasingly dominating the drug development pipeline, and the
very nature of genomics is unprecedented scientific precision—working at the
cellular, genetic, and molecular levels in living organisms to identify genetic
expression, to reveal the origins and progression of disease, and to make
connections between the two and develop drugs based upon those
connections.279 Regulatory reform is needed to make the science standard for
human clinical trials responsive to the significance of human individuality and
variability—factors recognized innately in both genomics and the patientcentered practice of medicine.
This Article has proposed law-policy reforms to infuse an alternative
science methodology into human clinical research for drug development—
SSRD. SSRD shares the responsiveness of genetics-based R&D to the reality
of individual human variability, and an SSRD complement to GD could prove
a means to move drug development through its present state of puberty
between the crude science past and genetics-based future.280 “The single
subject design has been successful in illuminating research findings across a
variety of disciplines. It overcomes some of the inherent limitations found in
large-scale clinical trials, in that treatments are tailored for unique individuals
and can also be modified over time.”281
The proposals to promote SSRD put forth in this Article are based upon
commercial incentives and programs that have endured the threat of legal
challenges—the ODA and the BPCA.282 The FDA has successfully used ODA
and BPCA to get needed clinical research done on small disease groups and
children that industry had avoided. This Article also proposes to infuse SSRD
into human clinical research through a billion-dollar government center
recently established to help industry create new drugs.283 The objective, as
expressed by NIH Director Francis Collins who will direct the center and
headed the U.S. government’s effort to map the human genome, is to convert
contemporary genetic science accomplishments into clinical applications that

278. Food and Drug Administration Amendmendts Act of 2007, Pub. L. No. 110-85, 121 Stat.
823 (codified as amended in scattered sections of 21 U.S.C.); see supra notes 23–25, 67 and
accompanying text; supra Part II.
279. See supra Part II.B.
280. See supra Parts III.A–B.
281. JANOSKY ET AL., supra note 6, at 95.
282. See supra notes 35–36 and accompanying text.
283. See Harris, supra note 2.
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improve human health and move industry out of its fifteen year slump in new
drug approvals.284
The biopharmaceutical sectors have the resources and capabilities to meet
a higher science standard in clinical research than GD—a standard that has
resulted in ongoing drug underdevelopment.285 SSRD is an opportunity to
introduce a gold standard that actually glitters in an age of genomics and shifts
drug development in the direction of needed improvements to human health.

284. Id.
285. See supra Part II.

